Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides her impression of the Phase 3 ICARIA-MM study investigating isatuximab in relapsed/refractory multiple myeloma patients
Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how JNJ-4528 differs from other CAR-T products
Noa Biran, MD, tells us about the outcomes of the CARTITUDE-1 study
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us about the outcomes of the CARTITUDE-1 investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma
Amrita Krishnan, MD, elaborates on BCMA-directed strategies for multiple myeloma patients
Dr. Krishnan, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, elaborates on BCMA-directed strategies for multiple myeloma patients
Amrita Krishnan, MD, tells us about the outcomes of the CARTITUDE-1 study presented at ASH 2019
Dr. Krishnan, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, tells us about the outcomes of the CARTITUDE-1 study investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma
Amrita Krishnan, MD, tells us about the results of the Phase 1 study investigating CC-93269 in MM
Dr. Krishnan, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, tells us about the results of the Phase 1 study investigating CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in patients with relapsed/refractory multiple myeloma (MM)
James Essell, MD, offers his impression the data investigating the bi-specific CAR-T cell therapy
Dr. Essell, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, offers his impression the recent data investigating the bi-specific CAR-T cell therapy
James Essell, MD, discusses the integration of stem cell transplantation in the treatment of myeloma
Dr. Essell, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses the integration of stem cell transplantation into the treatment of myeloma
Peter M. Voorhees, MD, explains how daratumumab is changing the way MM patients are treated today
Dr. Voorhees, Associate Professor, Myeloma Program, Levine Cancer Center Institute, explains how daratumumab is changing the way multiple myeloma (MM) patients are treated today
Peter M. Voorhees, MD, summarizes the outcomes of the Phase 2 Griffin study in newly diagnosed MM
Dr. Voorhees, Associate Professor, Myeloma Program, Levine Cancer Center Institute, summarizes the design and outcomes of the Phase 2 Griffin study in newly diagnosed multiple myeloma (MM) patients
Robert Rifkin, MD, FACP, on the role of daratumumab as maintenance therapy in the management of MM
Dr. Rifkin, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, explains the role of daratumumab as a maintenance therapy in the management of multiple myeloma (MM)
Robert Rifkin, MD, FACP, offers opinion on the most promising studies in MM presented at ASH 2019
Dr. Rifkin, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, offers opinion on the most promising studies in multiple myeloma (MM) presented at ASH 2019
Robert Rifkin, MD, FACP, tells us about the outcomes of the LYRA study presented at ASH 2019
Dr. Rifkin, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, tells us about the outcomes of the LYRA study investigating the management of infusion reactions to daratumumab in multiple myeloma
Andrew Cowan, MD, elaborates on the role of isatuximab in the management of multiple myeloma
Dr. Cowan, Assistant Professor, Hematology/Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, differentiates between various anti-CD-38 monoclonal antibodies and elaborates on the role of isatuximab in the management of multiple myeloma
Andrew Cowan, MD, on the most promising clinical data in multiple myeloma presented at ASH 2019
Dr. Cowan, Assistant Professor, Hematology/Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, elaborates on the most promising clinical data in multiple myeloma presented at ASH 2019
Andrew Cowan, MD, provides an overview of the use of CAR-T cell therapy in multiple myeloma
Dr. Cowan, Assistant Professor, Hematology/Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, provides an overview of the use of CAR-T cell therapy in multiple myeloma
Andrew Cowan, MD, discusses the role of human BCMA CAR-T cells in the management of multiple myeloma
Dr. Cowan, Assistant Professor, Hematology/Oncology, University of Washington School of Medicine, Seattle Cancer Care Alliance, discusses the role of human BCMA CAR-T cells in the management of multiple myeloma (MM)
Joshua Richter, MD, on the Phase 3 ICARIA-MM study from the 61st ASH Annual Meeting and Exposition
Dr. Richter, Assistant Professor, Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mt. Sinai School of Medicine, considers the Phase 3 ICARIA-MM study investigating isatuximab in relapsed/refractory multiple myeloma patients
Joshua Richter, MD, provides opinion on the role of BCMA CAR-T cells in the management of MM
Dr. Richter, Assistant Professor, Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mt. Sinai School of Medicine, provides opinion on the role of BCMA CAR-T cells in the management of multiple myeloma (MM)
Parameswaran Hari, MD, MRCP, offers his impression of the Phase 3 ICARIA-MM trial from ASH 2019
Dr. Hari, Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, offers his impression of the Phase 3 ICARIA-MM trial investigating isatuximab in relapsed/refractory multiple myeloma
Parameswaran Hari, MD, MRCP, on novel combination treatment options & sequencing strategies in MM
Dr. Hari, Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, explains how novel combination treatment options and sequencing strategies are used to manage relapsed/refractory multiple myeloma (MM)
Parameswaran Hari, MD, MRCP, considers the role of stem cell transplantation in myeloma
Dr. Hari, Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, elaborates on the role of stem cell transplantation in the treatment of myeloma
Parameswaran Hari, MD, MRCP, tells us about the design & outcomes of the STORM and Mammoth studies
Dr. Hari, Chief, Professor, Hematology/Medical Oncology, Medical College of Wisconsin, tells us about the design and outcomes of the STORM and Mammoth studies, investigating refractory multiple myeloma (MM) patients treated with selinexor plus dexamethasone or conventional care
Deepu Madduri, MD, explains how JNJ-4528 differs from other CAR-T products
Dr. Madduri, Assistant Professor, Medicine, Hematology and Medical Oncology, The Mount Sinai Hospital, explains how JNJ-4528 differs from other CAR-T products
Deepu Madduri, MD, on how CAR-T cell therapy plays a role in the management of multiple myeloma
Dr. Madduri, Assistant Professor, Medicine, Hematology and Medical Oncology, The Mount Sinai Hospital, on how CAR-T cell therapy plays a role in the management of multiple myeloma
Deepu Madduri, MD, elaborates on the outcomes of the CARTITUDE-1 study
Dr. Madduri, Assistant Professor, Medicine, Hematology and Medical Oncology, The Mount Sinai Hospital, tells us about the outcomes of the CARTITUDE-1 study investigating JNJ-4528 directed against BCMA in relapsed refractory multiple myeloma
Saad Usmani, MD, FACP, considers data in smoldering MM coming out of ASCO 2019
Dr. Usmani, Chief, Plasma Cell Disorders Program, Director, Clinical Research in Hematologic Malignancies, Levine Cancer Institute/Atrium Health, Clinical Professor of Medicine, UNC Chapel Hill School of Medicine, shares his impressions of the data in smoldering multiple myeloma (MM) presented at the 2019 ASCO Annual Meeting
Parameswaran Hari, MD, discusses the role of CAR-T therapy in multiple myeloma
Dr. Hari, Professor of Hematology, Medical College of Wisconsin, discusses the role of CAR-T therapy in multiple myeloma (MM)
Parameswaran Hari, MD, considers whether isatuximab will become a viable option in MM
Dr. Hari, Professor of Hematology, Medical College of Wisconsin, considers whether isatuximab will become a viable option in relapsed/refractory multiple myeloma (MM)
Saad Usmani, MD, FACP, regarding outcomes from the MAIA study presented at ASCO 2019
Dr. Usmani, Chief, Plasma Cell Disorders Program, Director, Clinical Research in Hematologic Malignancies, Levine Cancer Institute/Atrium Health, Clinical Professor of Medicine, UNC Chapel Hill School of Medicine, shares outcomes from the MAIA study comparing daratumumab + lenalidomide + dexamethasone versus lenalidomide + dexamethasone in elderly multiple myeloma patients
Parameswaran Hari, MD, elaborates on the outcome from the ECOG trial in SMM
Dr. Hari, Professor of Hematology, Medical College of Wisconsin, tells us about the outcomes of the ECOG trial in smouldering multiple myeloma (SMM) presented at the 2019 ASCO Annual Meeting
Robert M. Rifkin, MD, FACP, speculates on the promise of bispecific antibodies in MM
Dr. Rifkin, Medical Director, McKesson Biosimilars, Associate Chair, Hematology Research, Disease Lead, Myeloma, The US Oncology Network, Rocky Mountain Cancer Centers, tells us about the promise of bispecific antibodies in multiple myeloma (MM) treatment
Robert M. Rifkin, MD, FACP, discusses maintenance regimens for multiple myeloma
Dr. Rifkin, Medical Director, McKesson Biosimilars, Associate Chair, Hematology Research, Disease Lead, Myeloma, The US Oncology Network, Rocky Mountain Cancer Centers, discusses current maintenance regimens for multiple myeloma
Paul G. Richardson, MD, shares clinical results from the ECOG trial in smoldering MM
Dr. Richardson, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma Center, Institute Physician, RJ Corman Professor of Medicine, Harvard Medical School, shares clinical results from the ECOG trial in smoldering multiple myeloma (MM)
Robert M. Rifkin, MD, FACP, considers progression-free survival in MM when treating with isatuximab
Dr. Rifkin, Medical Director, McKesson Biosimilars, Associate Chair, Hematology Research, Disease Lead, Myeloma, The US Oncology Network, Rocky Mountain Cancer Centers, discusses the significance of the prolonged progression-free survival in patients with relapsed/refractory multiple myeloma (MM) when treating with isatuximab
Paul G. Richardson, MD, considers whether isatuximab shows promise as a treatment option for MM
Dr. Richardson, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma Center, Institute Physician, RJ Corman Professor of Medicine, Harvard Medical School, compares isatuximab and daratumumab and considers whether isatuximab shows promise as a treatment option for relapsed/refractory multiple myeloma (MM)
Robert M. Rifkin, MD, FACP, explains how isatuximab differs from daratumumab
Dr. Rifkin, Medical Director, McKesson Biosimilars, Associate Chair, Hematology Research, Disease Lead, Myeloma, The US Oncology Network, Rocky Mountain Cancer Centers, explains how isatuximab differs from daratumumab and whether the drug shows promise as a treatment for relapsed/refractory multiple myeloma (MM)
Paul G. Richardson, MD, considers progression-free survival in MM when treating with isatuximab
Dr. Richardson, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma Center, Institute Physician, RJ Corman Professor of Medicine, Harvard Medical School, discusses the significance of the prolonged progression-free survival in patients with relapsed/refractory multiple myeloma (MM) when treating with isatuximab
Robert M. Rifkin, MD, FACP, discusses outcomes from the ECOG trial in smoldering multiple myeloma
Dr. Rifkin, Medical Director, McKesson Biosimilars, Associate Chair, Hematology Research, Disease Lead, Myeloma, The US Oncology Network, Rocky Mountain Cancer Centers, discusses outcomes from the ECOG trial in smoldering multiple myeloma (MM) presented at the 2019 ASCO Annual Meeting
Paul G. Richardson, MD, regarding the updated FORTE trial data in multiple myeloma
Dr. Richardson, Clinical Program Leader, Director of Clinical Research, Jerome Lipper Multiple Myeloma Center, Institute Physician, RJ Corman Professor of Medicine, Harvard Medical School, tells us about the updated FORTE trial data regarding transplant in multiple myeloma (MM)
Amrita Krishnan, MD, considers whether KRD will replace stem cell transplant
Dr. Krishnan, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, considers whether KRD will replace stem cell transplant
Amrita Krishnan, MD, discusses the future of isatuximab in the treatment of relapsed/refractory MM
Dr. Krishnan, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, discusses the future of isatuximab as a viable option in relapsed/refractory multiple myeloma (MM)
Amrita Krishnan, MD, regarding outcomes from the CASSIOPEIA trial presented at ASCO '19
Dr. Krishnan, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, regarding outcomes from the CASSIOPEIA trial involving daratumumab + VTD in multiple myeloma
Amrita Krishnan, MD, tells us about the outcomes of the ECOG trial in SMM
Dr. Krishnan, Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research, Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, tells us about the outcomes of the ECOG trial in smoldering multiple myeloma (SMM) presented at ASCO 2019
Sen Zhuang, MD, PhD, shares details from the LCAR-838M study in relapsed/refractory MM
Dr. Zhuang, VP, Oncology Clinical Research, Janssen, tells us about the results of the LCAR-838M study in relapsed/refractory multiple myeloma (MM) presented at the 2018 ASH Annual Meeting and Exposition
Sen Zhuang, MD, PhD, speculates on how LCAR-838M may impact the treatment of MM
Dr. Zhuang, VP, Oncology Clinical Research, Janssen, offers opinion on how LCAR-838M may impact the treatment of multiple myeloma (MM)
Sen Zhuang, MD, PhD, regarding the development of LCAR-B38M
Dr. Zhuang, VP, Oncology Clinical Research, Janssen, shares how the CAR-T product (LCAR-B38M) is being studied and how it differs from products currently on the market
Rod A. Humerickhouse, MD, PhD, elaborates on venetoclax in treatment of MM
Dr. Humerickhouse, Group Project Leader, Oncology Development, AbbVie, tells us how venetoclax should be used in the treatment of relapsed/refractory multiple myeloma (MM)
Katja Weisel, MD, provides opinion on anti-BCMA CAR-T cell therapy in multiple myeloma
Dr. Weisel, Head of the Myeloma Center, University of Tubingen, discusses anti-BCMA CAR-T cell therapy treatment for multiple myeloma (MM) patients
Habte Yimer, MD, considers the outcomes of the GRIFFIN study in multiple myeloma
Dr. Yimer, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, tells us about the outcomes of the GRIFFIN study, a Phase 2 clinical study examining daratumumab, bortezomib, lenalidomide, and dexamethasone versus RVD in newly diagnosed multiple myeloma (MM) patients
Katja Weisel, MD, discusses current maintenance regimens in multiple myeloma
Dr. Weisel, Head of the Myeloma Center, University of Tubingen, explains how maintenance regimens in multiple myeloma may change as a result of the clinical presentations from the 2018 ASH Annual Meeting and Exposition
Habte Yimer, MD, speculates on the future of anti-BCMA CAR-T cell therapy
Dr. Yimer, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, shares thoughts on whether anti-BCMA CAR-T cell therapy looks promising as a treatment option for multiple myeloma (MM) patients
Katja Weisel, MD, elaborates on the outcomes of the TOURMALINE-MM3 study
Dr. Weisel, Head of the Myeloma Center, University of Tubingen, tells us how the outcomes of the TOURMALINE-MM3 study may or may not change the way she treats multiple myeloma (MM) patients
Habte Yimer, MD, regarding the POLLUX and CASTOR studies presented at ASH 2018
Dr. Yimer, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, offers opinion on how the the POLLUX and CASTOR studies shape thinking regarding the use of daratumumab for multiple myeloma (MM) patients
Katja Weisel, MD, shares outcomes of the POLLUX and CASTOR studies from ASH 2018
Dr. Weisel, Head of the Myeloma Center, University of Tubingen, offers opinion on how the POLLUX and CASTOR studies shape her thinking regarding the use of daratumumab for multiple myeloma (MM) patients
Habte Yimer, MD, regarding the Lyra trial in newly diagnosed multiple myeloma presented at ASH 2018
Dr. Yimer, Hematologist/Oncologist, US Oncology Research Executive Council Member, Texas Oncology, discusses the impact of Lyra, a Phase 2 study investigating daratumumab in newly diagnosed multiple myeloma (MM) patients
Peter Vorhees, MD, describes what regimens are being used for multiple myeloma patients today
Dr. Vorhees, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, describes what maintenance regimens are being used for multiple myeloma patients today and if that will change as a result of the clinical presentations at ASH
Peter Vorhees, MD, discusses the outcomes of the TOURMALINE-MM3 study in MM
Dr. Vorhees, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, on if the outcomes of the TOURMALINE-MM3 study will change the way multiple myeloma patients who have had at least one prior therapy are treated
Peter Vorhees, MD, discusses outcomes of the ALCYONE trial in multiple myeloma patients
Dr. Vorhees, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, discusses outcomes of the ALCYONE trial in transplant-ineligible newly diagnosed multiple myeloma patients
Rafael Fonseca, MD, on the effectiveness of anti-BCMA CAR-T cell therapy in multiple myeloma
Dr. Fonseca, Hematologist, Mayo Clinic, considers whether anti-BCMA CAR-T cell therapy is a promising treatment option for multiple myeloma (MM) patients
Rafael Fonseca, MD, discusses maintenance regimens for multiple myeloma
Dr. Fonseca, Hematologist, Mayo Clinic, shares details regarding maintenance regimens for multiple myeloma (MM) and the impact of the clinical presentations from the 2018 ASH Annual Meeting and Exposition
Rafael Fonseca, MD, regarding the TOURMALINE-MM3 study in multiple myeloma
Dr. Fonseca, Hematologist, Mayo Clinic, tells us how the outcomes of the TOURMALINE-MM3 study may impact the way he treats multiple myeloma (MM) patients who have had at least one prior therapy
Rafael Fonseca, MD, elaborates on the outcomes of the POLLUX and CASTOR studies in MM
Dr. Fonseca, Hematologist, Mayo Clinic, explains how the POLLUX and CASTOR studies presented at the 2018 ASH Annual Meeting and Exposition shape his thinking regarding the use of daratumumab for multiple myeloma (MM) patients
Rafael Fonseca, MD, discusses frontline multiple myeloma treatment patterns
Dr. Fonseca, Hematologist, Mayo Clinic, tells us about frontline multiple myeloma (MM) treatment patterns and attrition rates in subsequent lines of therapy
Edward Copelan, MD, considers the role of allogeneic transplantation in lymphoma & multiple myeloma
Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, considers how allogeneic transplantation is being optimized for lymphoma and multiple myeloma patients and how does it compares with CAR-T therapies
Nikhil Munshi, MD, discusses the outcomes of the TOURMALINE-MM3 study in multiple myeloma
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, explores how the outcomes of the TOURMALINE-MM3 study will or will not change the way multiple myeloma patients who have had at least one prior therapy are treated
Nikhil Munshi, MD, discusses the POLLUX and CASTOR studies regarding the use of daratumumab in MM
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, discusses how the POLLUX and CASTOR studies impact the use of daratumumab in multiple myeloma patients
Nikhil Munshi, MD, regarding the outcomes of the CA204-142 study from ASH 2018
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, tells us about the outcomes of the CA204-142 study investigating elotuzumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (MM)
Nikhil Munshi, MD, considers how ID2 function impacts oncogenesis in multiple myeloma
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School, explains how ID2 function impacts oncogenesis in multiple myeloma (MM)
Andrew Pecora, MD, shares his thoughts on the necessity of allogeneic transplants to MML patients
Dr. Pecora, Chief Innovation Officer, Professor and Vice President of Cancer Services John Theurer Cancer Center, shares his thoughts on if there will be a day when it may not be necessary to give an allogeneic transplant to multiple myeloma and lymphoma patients
Nizar Bahlis, MD, speculates on the future of anti-BCMA CAR-T cell therapy in MM
Dr. Bahlis, University of Calgary, Calgary, provides opinion on whether anti-BCMA CAR-T cell therapy looks promising as a treatment option for multiple myeloma (MM) patients
Nizar Bahlis, MD, describes current maintenance regimens for multiple myeloma
Dr. Bahlis, University of Calgary, Calgary, discusses current maintenance regimens for multiple myeloma (MM) and how they may change as a result of the clinical studies presented at the ASH 2018 Annual Meeting and Exposition
Nizar Bahlis, MD, discusses the outcomes of the TOURMALINE-MM3 study from ASH 2018
Dr. Bahlis, University of Calgary, Calgary, tells us how the outcomes of the TOURMALINE-MM3 study may change the way he treats multiple myeloma (MM)
Nizar Bahlis, MD, regarding the impact of the POLLUX and CASTOR studies from ASH 2018
Dr. Bahlis, University of Calgary, Calgary, shares how the POLLUX and CASTOR studies presented at the 2018 ASH Annual Meeting and Exposition shape his thinking regarding the use of daratumumab in multiple myeloma (MM) treatment
Robert Rifkin, MD, explains whether or not anti-BCMA CAR-T cell therapy looks promising
Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, explains whether or not anti-BCMA CAR-T cell therapy looks promising as a treatment for multiple myeloma patients
Robert Rifkin, MD, discusses the outcomes of the TOURMALINE-MM3 study
Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, on if the outcomes of the TOURMALINE-MM3 study will or will not change the way multiple myeloma patients are treated
Robert Rifkin, MD, talks about what clinical data could change the way multiple myeloma is treated
Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, talks about what clinical data has been presented at ASH could change the way penta-refractory multiple myeloma patients are treated
Ravi Vij, MD, considers anti-BCMA CAR-T cell therapy in multiple myeloma
Dr. Vij, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, considers anti-BCMA CAR-T cell therapy as a promising treatment option for multiple myeloma (MM) patients
Ravi Vij, MD, discusses current maintenance regimens for multiple myeloma
Dr. Vij, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, elaborates on current maintenance regimens for multiple myeloma patients and how clinical studies presented at ASH 2018 may influence these regimens
Ravi Vij, MD, regarding the POLLUX and CASTOR clinical studies in multiple myeloma
Dr. Vij, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, elaborates on the POLLUX and CASTOR studies and whether they shape his thinking regarding the use of daratumumab in the treatment of multiple myeloma (MM)
Andrzej Jakubowiak, MD, shares thoughts on the POLLUX and CASTOR clinical studies
Dr. Jakubowiak, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, provides opinion on how the POLLUX and CASTOR studies shaped his thinking regarding the use of daratumumab for the treatment of multiple myeloma (MM)
Andrzej Jakubowiak, MD, PhD, discusses maintenance regimens in treatment of multiple myeloma
Dr. Jakubowiak, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, shares how maintenance regimens for multiple myeloma (MM) patients may change as a result of clinical presentations at the ASH 2018 Annual Meeting and Exposition
Andrzej Jakubowiak, MD, PhD, regarding the ALCYONE trial presented at ASH 2018
Dr. Jakubowiak, Professor of Medicine Director, Myeloma Program, University of Chicago Medical Center, tells us about the ALCYONE study examining the addition of daratumumab to bortezomib, melphalan, and prednisone in patients with transplant-ineligible newly diagnosed multiple myeloma (MM)
Andrzej Jakubowiak, MD, discusses the outcomes of the GRIFFIN study from ASH 2018
Dr. Jakubowiak, Professor of Medicine Director, Myeloma Program University of Chicago Medical Center, tells us about the outcomes of the GRIFFIN study, a Phase 2 clinical study examining daratumumab, bortezomib, lenalidomide, and dexamethasone versus RVD in newly diagnosed multiple myeloma (MM) patients
Sundar Jagannath, MD, discusses the role of checkpoint inhibitors in treatment of MM
Dr. Jagannath, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, offers opinion on the role of checkpoint inhibitors in the treatment of multiple myeloma (MM)
Sundar Jagannath, MD, regarding proteasome inhibitors in the treatment of MM
Dr. Jagannath, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, on whether data supports the integration of proteasome inhibitors in treatment algorithms for multiple myeloma (MM)
Maria-Victoria Mateos, MD, elaborates on the TOURMALINE-MM3 presented at ASH 2018
Dr. Mateos, Associate Professor of Medicine, University of Salamanca, gives her impressions of the TOURMALINE-MM3 study presented at the 2018 ASH Annual Meeting and Exposition and whether it will change maintenance following ASCT in newly diagnosed multiple myeloma (MM) patients
Maria-Victoria Mateos, MD, on the addition of daratumumab to revlimid/dexamethasone in MM
Dr. Mateos, Associate Professor of Medicine, University of Salamanca, explains how the addition of daratumumab to revlimid/dexamethasone enhances outcomes in newly diagnosed multiple myeloma (MM) patients
Sundar Jagannath, MD, considers maintenance regimens for multiple myeloma (MM) patients
Dr. Jagannath, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, offers opinion on clinical presentations from the ASH 2018 Annual Meeting and Exposition and the influence on maintenance regimens for multiple myeloma (MM) patients
Sundar Jagannath, MD, elaborates on the outcomes of CA204-142 in MM
Dr. Jagannath, Professor of Medicine, Hematology and Medical Oncology, Mount Sinai School of Medicine, tells us about the outcomes of the CA204-142 study investigating elotuzumab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (MM)
Maria-Victoria Mateos, MD, regarding the CASTOR trial presented at ASH 2018
Dr. Mateos, Associate Professor of Medicine, University of Salamanca, tells us about the design and outcomes of the CASTOR study investigating bortezomib and dexamethasone +/- daratumumab in relapsed/refractory multiple myeloma
Maria-Victoria Mateos, MD, shares outcomes from the ALCYONE study in MM
Dr. Mateos, Associate Professor of Medicine, University of Salamanca, tells us about the results of the ALCYONE study looking at daratumumab plus bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone in transplant-ineligible newly diagnosed multiple myeloma (MM) patients
David Siegel, MD, explains the results of MM014 study presented at ASH
Dr. Siegel, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, explains the results of the MM014 study presented here at ASH
David Siegel, MD, discusses anti-BCMA CAR-T cell therapy for multiple myeloma patients
Dr. Siegel, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, shares his thoughts on anti-BCMA CAR-T cell therapy and if it looks promising as a treatment for multiple myeloma patients
David Siegel, MD, talks about the TOURMALINE-MM3 study and the treatment of multiple myeloma
Dr. Siegel, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, talks about how the outcomes of the TOURMALINE-MM3 study will or will not change how multiple myeloma patients are treated who have had at least one prior therapy
Andrew Pecora, MD, tells us about the results of the CPIT trial presented here at ASH
Dr. Pecora, Chief Innovation Officer, Professor and Vice President of Cancer Services, John Theurer Cancer Center, tells us about the results of the CPIT trial presented here at ASH
David Siegel, MD, shares his thoughts on the daratumamab studies presented at ASH 2018
Dr. Siegel, Hematologist/Oncologist, Hackensack University Medical Center, John Theurer Cancer Center, shares his thoughts on the daratumamab studies presented at the meeting
Ravi Vij, MD, on the outcomes of the TOURMALINE-MM3 study in multiple myeloma
Ravi Vij, MD, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, shares how the outcomes of the TOURMALINE-MM3 study will impact the way he treats multiple myeloma (MM) patients
Peter Vorhees, MD, discusses the outcomes of the GRIFFIN trial in multiple myeloma
Peter Vorhees, MD, Director of Outreach and Clinical Operations, Department of Hematologic Oncology and Blood Diosrders, Levine Cancer Institute, discusses the outcomes of the GRIFFIN trial in multiple myeloma at ASH 2018
Noa Biran, MD, on combination carfilzomib & daratumumab in revlimid-refractory multiple myeloma
Dr. Biran shares her thoughts on the promising combination of carfilzomib and daratumumab in revlimid-refractory multiple myeloma patients
Noa Biran, MD, considers whether VPd is effective in relapsed multiple myeloma
Dr. Biran offers opinion on whether bortezomib, pomalidomide, and low-dose dexamethasone (VPd) is effective in relapsed multiple myeloma patients.
Noa Biran, MD, on the logistics involved in delivering CAR-T in the BB2121 study
Dr. Biran tells us about the logistics involved in delivering CAR-T in the BB2121 study in multiple myeloma patients
Noa Biran, MD, on the impact of the BB2121 study in multiple myeloma
Dr. Biran considers the impact of the BB2121 study in multiple myeloma patients and how the results compare to the standard of care
Noa Biran, MD, shares some of the exciting clinical advances presented at ASCO 2018
Dr. Biran offers her opinion on the most exciting clinical data presented at the 2018 ASCO Annual Meeting
Jesus San-Miguel, MD, on the role of daratumumab in the front-line setting in multiple myeloma (MM)
Dr. San-Miguel discusses the role of daratumumab in the front-line setting in multiple myeloma (MM) patients
Edward A. Copelan, MD, on allogeneic transplantation & CAR T-cell therapy in lymphoma and myeloma
Dr. Copelan elaborates on how allogeneic transplantation is being optimized for lymphoma and myeloma patients and how it compares with CAR T-cell therapy
Habte Yimer, MD, on daratumumab, cyclophosphamide, bortezomib, & dexamethasone in relapsed MM
Dr. Yimer considers the safety of combination daratumumab, cyclophosphamide, bortezomib, and dexamethasone in previously untreated and relapsed multiple myeloma (MM) patients
Parameswaran Hari, MD, MRCP, MS, considers the remaining unmet medical needs in MM
Dr. Hari describes the remaining major unmet medical needs in the treatment of multiple myeloma (MM) and the proportion of his patients that fall into this unmet need category
Parameswaran Hari, MD, MRCP, MS, discusses the clinical relevance of minimal residual disease
Dr. Hari elaborates on the clinical relevance of minimal residual disease for patients today
Parameswaran Hari, MD, MRCP, MS, provides an update on how MM patients are staged at diagnosis
Dr. Hari tells us how multiple myeloma (MM) patients are staged at initial diagnosis
Parameswaran Hari, MD, MRCP, MS, on how the field of immunotherapy is evolving for MM patients
Dr. Hari offers his thoughts on how the field of immunotherapy is evolving for multiple myeloma (MM) patients
Parameswaran Hari, MD, MRCP, MS, on checkpoint inhibitors and MM treatment algorithms
Dr. Hari explains how checkpoint inhibitors are being integrated into multiple myeloma (MM) treatment algorithms today
Paul Richardson, MD, on the importance of real world evidence (RWE)
Dr. Richardson provides insight into the importance of real world evidence (RWE) and how clinical data compares with actual usage in multiple myeloma patients
Paul Richardson, MD, shares the efficacy outcomes of GSK-916 in relapsed/refractory MM patients
Dr. Richardson describes the efficacy outcomes of the BCMA immune conjugate (GSK-916) in relapsed/refractory multiple myeloma patients
Paul Richardson, MD, on adding CAR T-cell therapy to multiple myeloma treatment algorithms
Dr. Richardson elaborates on adding CAR T-cell therapy into treatment algorithms for multiple myeloma
Robert M. Rifkin, MD, on excluding transplantation from MM treatment algorithms
Dr. Rifkin on if we are getting closer to excluding transplantation from Multiple Myeloma treatment algorithms
Robert M. Rifkin, MD, discusses if COMPASS is close to its goal of achieving whole genome sequencing
Dr. Rifkin discusses if COMPASS, the multiple myeloma registry, is getting closer to its goal of achieving whole genome sequencing
Robert M. Rifkin, MD, on the Connect Multiple Myeloma patient registry improving characterization
Dr. Rifkin on if the Connect Multiple Myeloma patient registry can help improve the characterization of MM
Robert M. Rifkin, MD, on how the Connect Multiple Myeloma patient registry is helping patients
Dr. Rifkin on how the Connect Multiple Myeloma patient registry is helping patients
David S. Siegel, MD, shares his thoughts on the most exciting clinical trial presented at ASH 2017
Dr. Siegel shares his thoughts on the most exciting clinical trial presented at ASH 2017
David S. Siegel, MD, discusses proteasome inhibitors and Multiple Myeloma
Dr. Siegel discusses which proteasome inhibitor delivers the best efficacy in the front line treatment of Multiple Myeloma
David S. Siegel, MD, discusses how stem cell transplant figures into MM treatment algorithms
Dr. Siegel discusses how autologous stem cell transplant figures into Multiple Myeloma treatment algorithms
David S. Siegel, MD, on how molecular profiling is helping drive treatment strategies
Dr. Siegel on the Multiple Myeloma Research Foundation (MMRF) Molecular Profiling Protocol and how molecular profiling is helping drive treatment strategies
C. Ola Landgren, MD, discusses remaining major unmet medical needs for MM
Dr. Landgren discusses remaining major unmet medical needs for mutliple myeloma and what proportion of patients fall into this unmet need category
C. Ola Landgren, MD, discusses risk factors for developing AML or MDS after treatment of MM
Dr. Landgren discusses risk factors for developing acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) after treatment of Multiple Myeloma
C. Ola Landgren, MD, discusses continuous therapy vs fixed duration therapy in MM patients
C. Ola Landgren, MD, discusses if continuous therapy is a better strategy than fixed duration therapy in Multiple Myeloma patients
C. Ola Landgren, MD, on MRD as a legitimate surrogate endpoint in multiple myeloma clinical trials
Dr. Landgren on MRD as a legitimate surrogate endpoint in multiple myeloma clinical trials
Sagar Lonial MD, FACP, on MM patients not responding to monotherapy and combination regimens
Dr. Lonial on characteristics of Multiple Myeloma patients that do not respond to current monotherapy and combination regimens
Sagar Lonial MD, FACP, discusses unmet need for multiple myeloma patients
Given the many novel therapy introductions over the past 5 years in Multiple Myeloma as monotherapy, Dr. Lonial discusses the remaining unmet needs if any and what proportion of patients fall into this category
Sagar Lonial MD, FACP, on predicting venetoclax sensitivity in MM using biologic active assays
Dr. Lonial on predicting venetoclax sensitivity in multiple myeloma using biologic active assays
Sagar Lonial MD, FACP on whether relapsed multiple myeloma patients should be profiled molecularly
Dr. Lonial on whether relapsed multiple myeloma patients should be profiled molecularly
David Siegel, MD, PhD, on pomalidomide as an effective salvage therapy for MM patients
Dr. Siegel, Chief, Multiple Myeloma, John Theurer Cancer Center, elaborates on whether pomalidomide can be an effective salvage therapy for multiple myeloma patients progressing on lenalidomid
David Siegel, MD, PhD, considers the effectiveness of CAR T-cell therapy in treating MM
Dr. Siegel, Chief, Multiple Myeloma, John Theurer Cancer Center, elaborates on the effectiveness of CAR T-cell therapy in treating multiple myeloma patients
David Siegel, MD, PhD, on pembrolizumab and lenalidomide in multiple myeloma treatment
Dr. Siegel, Chief, Multiple Myeloma, John Theurer Cancer Center, considers whether combining pembrolizumab and lenalidomide is effective when managing multiple myeloma patients
Noa Biran, MD, on what physicians should be aware of when sequencing agents in treating MM
Dr. Biran, Associate Professor, Hematologists/Oncologists, Multiple Myeloma Division, John Theurer Cancer Center, describes what physicians should be aware of when sequencing agents in the treatment of multiple myeloma
Noa Biran, MD, offers opinion on how personalized medicine will impact treatment of multiple myeloma
Dr. Biran, Associate Professor, Hematologists/Oncologists, Multiple Myeloma Division, John Theurer Cancer Center, explains how she expects personalized medicine to impact the treatment of multiple myeloma
Noa Biran, MD, shares how immunotherapies are being integrated into MM treatment algorithms
Dr. Biran, Associate Professor, Hematologists/Oncologists, Multiple Myeloma Division, John Theurer Cancer Center, describes how immunotherapies are being integrated into multiple myeloma treatment algorithms
Noa Biran, MD, reviews the data from ASCO regarding induction of newly diagnosed MM patients
Dr. Biran, Associate Professor, Hematologists/Oncologists, Multiple Myeloma Division, John Theurer Cancer Center, discusses the data presented at ASCO 2017 regarding induction of newly diagnosed MM patients
Sundar Jagannath, MD, on what we should know when sequencing agents in treating multiple myeloma
Dr. Jagannath, Director of Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, provides feedback on what physicians should know when sequencing agents in the treatment of multiple myeloma
Sundar Jagannath, MD, on the impact of personalized medicine in treatment of multiple myeloma
Dr. Jagannath, Director of Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, comments on how he expects personalized medicine to impact the treatment of multiple myeloma
Sundar Jagannath, MD, on immunotherapies and multiple myeloma treatment algorithms
Dr. Jagannath, Director of Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, elaborates on how immunotherapies are being integrated into multiple myeloma treatment algorithms
Sundar Jagannath, MD, discusses promising data from ASCO regarding multiple myeloma
Dr. Jagannath, Director of Multiple Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, outlines the most promising clinical data regarding the treatment of multiple myeloma presented at ASCO 2017
C. Ola Landgren, MD, PhD, on his optimism about the use of immunotherapies to treat MM patients
Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, discusses his optimism around the use of of immunotherapies treatment for multiple myeloma patients
C. Ola Landgren, MD, PhD, provides insight into the treatment algorithm for smoldering MM patients
Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, on the current treatment algorithm for smoldering myeloma patients
C. Ola Landgren, MD, PhD, on which multiple myeloma should be tested for MRD and why
Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, talks about which and why, multiple myeloma patients should be tested for MRD
Nikhil C. Munshi, MD, discusses his optimism about the use of immunotherapies to treat MM patients
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, discusses optimism about the use of immunotherapies to treat multiple myeloma patients
Nikhil C. Munshi, MD, discusses the exciting news at ASH multiple myeloma patients
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, on exciting news coming out of ASH multiple myeloma patients
Nikhil C. Munshi, MD, on how physicians should sequence therapies in untreated MM patients
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, provides viewpoint on how physicians should sequence therapies in untreated multiple myeloma patients
Parameswaran Hari, MD, talks about which stem cell transplantation studies are most exciting in MM
Dr. Hari, Professor of Hematology, Medical College of Wisconsin, speaks to which stem cell transplantation studies are most exciting and that may improve outcomes in multiple myeloma
Shaji Kumar, MD, shares his thoughts on whether multiple myeloma can be cured one day
Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, provides his thoughts on whether multiple myeloma can be cured one day
Shaji Kumar, MD, discusses sequencing agents in the treatment of multiple myeloma
Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, shares his thoughts on what physicians should be aware of when sequencing agents in the treatment of multiple myeloma
Shaji Kumar, MD, explains the impact personalized medicine will have on treatment of MM
Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, shares his thoughts on personalized medicine and its impact on the treatment of multiple myeloma
Shaji Kumar, MD, explains how immunotherapies are being integrated into treatment algorithms for MM
Dr. Kumar, Professor of Hematology, Mayo Clinic, Rochester, explains how immunotherapies are being integrated into multiple myeloma treatment algorithms
Michael Kauffman, MD, on evidence that Selinexor is helping relapsed, refractory MM patients
Dr. Kauffman, CEO Karyopharm Therapeutics, explains the clinical evidence on Selinexor that is helping relapsed, refractory multiple myeloma patients
C. Ola Landgren, MD, PhD, opines on how to base treatment decisions on MRD test results
Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, on how physicians should base treatment decisions on MRD test results for patients with multiple myeloma.
C. Ola Landgren, MD, PhD, relays his thoughts on the most exciting news at ASH for MM patients
Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, on what he found to be the most exciting news at ASH for multiple myeloma patients
Nikhil Munshi, MD, explains how the multiple myeloma genome project will personalize treatment of MM
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, on how the multiple myeloma genome project will help to personalize treatment of multiple myeloma
Nikhil C. Munshi, MD, discusses the goals for the multiple myeloma genome project
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, relays the end goals for the multiple myeloma genome project
Parameswaran Hari, MD, explains the effectiveness of novel immunotherapies in the treatment of multiple myeloma
Dr. Hari, Professor of Hematology, Medical College of Wisconsin, explains the effectiveness of novel immunotherapies in the treatment of multiple myeloma
Shaji Kumar, MD, discusses the most exciting treatment options for multiple myeloma today
Dr. Kumar, Professor of Medicine, Mayo Clinic, Rochester, shares his thoughts on the most exciting treatment options available in multiple myeloma
Alexander Lesokhin, MD discusses the development of immunotherapies for multiple myeloma patients
Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center explains how PD-L1 inhibitors and other immunotherapies are being developed for the treatment of multiple myeloma patients
Alexander Lesokhin, MD on the use of daratumumab to treat multiple myeloma patients
Alexander Lesokhin, MD, explains how daratumumab fits into treatment of relapsed multiple myeloma patients and how it may be eventually moved up into early stages of relapsed multiple myeloma patients
Alexander Lesokhin, MD provides an update on the CASTOR trial presented at ASCO 2016
Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center gives his take on the CASTOR clinical trial data which studied daratumumab (Darzalex) in relapsed/refractory multiple myeloma
Alexander Lesokhin, MD talks about the pros/cons of an all-oral regimen in the treatment of MM
Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center relays the pros and cons of an all-oral regimen including an oral proteasome inhibitor, for the treatment of multiple myeloma
Alexander Lesokhin, MD on sequencing therapies in relapsed multiple myeloma patients
Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center provides his perspective on how to sequence therapies in relapsed multiple myeloma patients
Alexander Lesokhin, MD explains therapy combinations for newly diagnosed multiple myeloma patients
Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center describes his approach to combining therapies for optimal outcomes in newly diagnosed multiple myeloma patients
Alexander Lesokhin, MD talks about newly diagnosed multiple myeloma patients
Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center, explains the patient selection considerations and treatment strategies for newly diagnosed multiple myeloma patients
Dana Farber IFM 2009 Phase III Study of the Intergroupe Francophone Du Myelome from ASH 2015
Saad Usmani, MD Levine Cancer Institute Charlotte, NC discusses the Dana Farber IFM 2009 Phase III Study of the Intergroupe Francophone Du Myelome from ASH 2015.
ASH 2015 Data Promises Immunotherapy Revolution in Multiple Myeloma with Pembrolizumab
Frederic Reu, MD Taussig Cancer Institute, Department of Hematology & Medical Oncology Cleveland Clinic talks about new ASH 2015 Data That Promises Immunotherapy Revolution in Multiple Myeloma with Pembrolizumab.
Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies
Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, offers opinion regarding off-the-shelf CAR-T cell therapies
Timothy Illidge, MD, PhD, describes the ECHELON-2 data presented at ASH 2019
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, describes the ECHELON-2 data presented at ASH 2019
Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the purpose of targeting peripheral t-cell lymphoma (PTCL)
Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)
Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, shares the the primary and secondary endpoints of the ECHELON-2 study
Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL data presented at ASH 2019 investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL)
Timothy Illidge, MD, PhD, on the impact of the ECHELON-2 trial data
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, on the impact of the ECHELON-2 trial data presented at ASH 2019
Ryan Lynch, MD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, considers whether minimal residual disease (MRD) is a valid endpoint when measuring the efficacy of treatment in chronic lymphocytic lymphoma (CLL)
Ryan Lynch, MD, considers the ideal patient profile for zanubrutinib in RR-MCL
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, considers the ideal patient profile for zanubrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL)
Christopher Yasenchak, MD, on the most impressive data in the treatment of Hodgkin’s lymphoma
Dr. Yasenchak, Medical Oncologist, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, discusses the most impressive clinical presentations from ASH 2019 in the treatment of Hodgkin’s lymphoma
Ryan Lynch, MD, tells us about the four-year update on the outcomes of the MURANO study
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, tells us about the four-year update on the outcomes of the MURANO study investigating venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic lymphoma (CLL)
Chaitra Ujjani, MD, considers the ideal patient profile for zanubrutinib in RR-MCL
Dr. Ujjani, Associate Professor, Seattle Cancer Care Alliance, University of Washington, Fred Hutchinson Cancer Research Center, considers the ideal patient profile for zanubrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL)
Angela Dispenzieri, MD, speculates on the the clinical impact of the TOURMALINE-AL1 study
Dr. Dispenzieri, Hematologist, Department of Hematology, Mayo Clinic, speculates on the the clinical impact of the TOURMALINE-AL1 study
Chaitra Ujjani, MD, considers how physicians should be thinking about BTK inhibitors in CLL
Dr. Ujjani, Associate Professor, Seattle Cancer Care Alliance, University of Washington, Fred Hutchinson Cancer Research Center, offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)
Angela Dispenzieri, MD, elaborates on the outcomes from the TOURMALINE-AL1 study
Dr. Dispenzieri, Hematologist, Department of Hematology, Mayo Clinic, elaborates on the outcomes from the TOURMALINE-AL1 study
Chaitra Ujjani, MD, tells us about Veneto-STOP study presented at ASH 2019
Dr. Ujjani, Associate Professor, Seattle Cancer Care Alliance, University of Washington, Fred Hutchinson Cancer Research Center, tells us about Veneto-STOP study presented at ASH 2019
Angela Dispenzieri, MD, shares the design of the TOURMALINE-AL1 study presented at ASH 2019
Dr. Dispenzieri, Hematologist, Department of Hematology, Mayo Clinic, shares the design of the TOURMALINE-AL1 study presented at ASH 2019
Jeffrey Sharman, MD, on the benefits of zanubrutinib as compared to other BTK inhibitors
Dr. Sharman, Director of Hematology Research, US Oncology Research, Willamette Valley Cancer Institute, on the benefits of zanubrutinib as compared to other BTK inhibitors in the management of lymphoma
Daniel Pollyea, MD, speculates on how oral HMAs will impact the landscape in myeloid malignancies
Dr. Pollyea, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, speculates on how the addition of oral HMAs will impact the landscape in myeloid malignancies
Jeffrey Sharman, MD, explains how we should be thinking about BTK inhibitors in the treatment of CLL
Dr. Sharman, Director of Hematology Research, US Oncology Research, Willamette Valley Cancer Institute, explains how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)
Daniel Pollyea, MD, provides opinion on current treatment strategies for elderly AML patients
Dr. Pollyea, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, provides opinion on current treatment strategies for elderly acute myeloid leukemia (AML) patients
Jeffrey Sharman, MD, shares updates from the CLL14 study presented at ASH 2019
Dr. Sharman, Director of Hematology Research, US Oncology Research, Willamette Valley Cancer Institute, shares updates from the CLL14 study presented at ASH 2019 and elaborates on the role of debulking plays in the management of chronic lymphocytic leukemia (CLL)
Daniel Pollyea, MD, discusses prognostic factors in acute myeloid leukemia (AML) patients
Dr. Pollyea, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses prognostic factors in acute myeloid leukemia (AML) patients
Jeffrey Sharman, MD, tells us about the design and outcomes of the Phase 3 ELEVATE TN from ASH 2019
Dr. Sharman, Director of Hematology Research, US Oncology Research, Willamette Valley Cancer Institute, tells us about the design and outcomes of the Phase 3 ELEVATE TN study, investigating acalabrutinib combined with obinutuzumab versus acalabrutinib alone versus obinutuzumab plus chlorambucil in patients with treatment-naive chronic lymphocytic leukemia (CLL)
Daniel Pollyea, MD, discusses the most promising emerging strategies in the management of AML
Dr. Pollyea, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses some of the novel agents, targeted therapies, and emerging strategies in the management of acute myelogenous leukemia (AML)
Andre Goy, MD, considers whether off-the-shelf CAR-T cell therapies are becoming a reality
Dr. Goy, Chairman, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers whether off-the-shelf CAR-T cell therapies are becoming a reality
Daniel Pollyea, MD, elaborates on the evolving treatment landscape in myelodysplastic syndromes
Dr. Pollyea, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, elaborates on how the treatment of myelodysplastic syndromes is changing as a result of clinical data presented at ASH 2019
Andre Goy, MD, on the TRANSCEND-CLL-004 data investigating the use of CAR-T cell therapy DLBCL
Dr. Goy, Chairman, John Theurer Cancer Center, Part of Hackensack University Medical Center, offers impressions of the TRANSCEND-CLL-004 data presented at ASH 2019 investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL)
Jae H. Park, MD, on incorporating CAR-T cell therapies into acute leukemia treatment algorithms
Dr. Park, Associate, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, offers opinion on whether there is sufficient evidence to incorporate CAR-T cell therapies into acute leukemia treatment algorithms
Andre Goy, MD, discusses the three-year survival analysis of the ZUMA-1 study from ASH 2019
Dr. Goy, Chairman, John Theurer Cancer Center, Part of Hackensack University Medical Center, discusses the three-year survival analysis of the ZUMA-1 study investigating axicabtagene ciloleucel in diffuse large b-cell lymphoma (DLBCL) presented at ASH 2019
Jae H. Park, MD, on the factors associated with improved survival after CD19 CAR-T cell therapy
Dr. Park, Associate, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, outlines the clinical factors associated with improved survival after CD19 CAR-T cell therapy in adult patients with B-cell acute lymphoblastic leukemia
Andre Goy, MD, regarding the ZUMA-2 study investigating anti-CD19 CAR-T cell therapy MCL
Dr. Goy, Chairman, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us about the results of the ZUMA-2 study investigating anti-CD19 CAR-T cell therapy in mantle cell lymphoma (MCL) patients
Jae H. Park, MD, regarding combination vemurafenib and obinutuzumab in hairy cell leukemia patients
Dr. Park, Associate, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, shares clinical outcomes from the investigation of the vemurafenib combined with obinutuzumab in patients with hairy cell leukemia
Constantine Tam, MBBS, MD, regarding the patient profile in MCL most suitable for zanubrutinib
Dr. Tam, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, regarding the ideal patient profile in relapsed or refractory mantle cell lymphoma (MCL) for treatment with zanubrutinib
Chaitra Ujjani, MD, tells us about the results of the Phase 3 ELEVATE TN study in CLL
Dr. Ujjani, Associate Professor, Seattle Cancer Care Alliance, University of Washington, Fred Hutchinson Cancer Research Center, tells us about the results of the Phase 3 ELEVATE TN study, investigating acalabrutinib combined with obinutuzumab or alone versus obinutuzumab plus chlorambucil in patients with treatment-naive chronic lymphocytic leukemia (CLL)
Angela Dispenzieri, MD, expands on the side effects from the TOURMALINE-AL1 study
Dr. Dispenzieri, Hematologist, Department of Hematology, Mayo Clinic, expands on the side effects from the TOURMALINE-AL1 study
Chaitra Ujjani, MD, offers her impression of the Phase 2 CAPTIVATE study in CLL
Dr. Ujjani, Associate Professor, Seattle Cancer Care Alliance, University of Washington, Fred Hutchinson Cancer Research Center, offers her impression of the Phase 2 CAPTIVATE study investigating the BTK inhibitor ibrutinib plus venetoclax in the first-line treatment of chronic lymphocytic leukemia (CLL)
Amrita Krishnan, MD, tells us about the Phase 3 Dreamm-3 study presented at ASH 2019
Dr. Krishnan, Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, tells us about the Phase 3 Dreamm-3 study, investigating belantamab versus pomalidomide and dexamethasone
David Andorsky, MD, defines RWE and explains how it compliments clinical trial results
Dr. Andorsky, Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers, defines real-world evidence (RWE) and explains how it compliments clinical trial results
Christopher Yasenchak, MD, on 1st line brentuximab vedotin + nivolumab in Hodgkin’s lymphoma
Dr. Yasenchak, Medical Oncologist, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, shares the design and results of the Phase 2 study investigating first-line brentuximab vedotin plus nivolumab in older patients with Hodgkin’s lymphoma
David Andorsky, MD, provides examples of how RWE has impacted the oncology community
Dr. Andorsky, Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers, provides examples of how real-world evidence (RWE) has impacted the oncology community
Christopher Yasenchak, MD, tells us about the patient profile most suited for zanubrutinib in MCL
Dr. Yasenchak, Medical Oncologist, Willamette Valley Cancer Institute and Research Center, Associate Chair, Hematology Research, US Oncology Research, tells us about the patient profile most suited for zanubrutinib in relapsed/refractory mantle cell lymphoma (MCL)
David Andorsky, MD, on the results of his RWE study investigating idelalisib in follicular lymphoma
Dr. Andorsky, Medical Oncologist, Associate Chair, US Oncology Research Group, shares the results of his real-world evidence (RWE) study investigating idelalisib in patients with follicular lymphoma
David Andorsky, MD, discusses the implications of real-world evidence for oncologists
Dr. Andorsky, Medical Oncologist, Associate Chair, US Oncology Research Group, Rocky Mountain Cancer Centers, considers what oncologists know about the implications of real-world evidence (RWE)
James Essell, MD, offers opinion on the future of off-the-shelf CAR-T cell therapy
Dr. Essell, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, offers opinion on the future of off-the-shelf CAR-T cell therapy
Amer Zeidan, MBBS, considers RWE in older patients with acute myeloid malignancies
Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine, Yale Cancer Center, considers what we have learned from understanding real-world evidence (RWE) in older patients with acute myeloid malignancies
James Essell, MD, regarding off-the-shelf CAR NK cell therapy in treating B-cell malignancies
Dr. Essell, Medical Director, Blood Cancer Center, The Jewish Hospital-Mercy Health, discusses off the-shelf CAR natural killer (CAR NK) cell therapy in treating B-cell malignancies
Amer Zeidan, MBBS, speculates on the role of immune checkpoint blockades in myeloid malignancies
Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine, Yale Cancer Center, speculates on the role of immune checkpoint blockades in myeloid malignancies
Amer Zeidan, MBBS, elaborates on the role of venetoclax in treatment of MDS
Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine, Yale Cancer Center, elaborates on the role of venetoclax in treatment of myelodysplastic syndromes (MDS)
Amer Zeidan, MBBS, on the role of oral therapies in the treatment of myeloid malignancies
Amer Zeidan, MBBS, Associate Professor of Hematology, Yale School of Medicine, Yale Cancer Center, explains how oral therapies will impact the treatment landscape in myeloid malignancies
Constantine Tam, MBBS, MD, considers the role of CAR-T cell therapy in chronic lymphocytic leukemia
Dr. Tam, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, considers the role of CAR-T cell therapy in chronic lymphocytic leukemia (CLL)
Constantine Tam, MBBS, MD, tells us about the Phase 2 CAPTIVATE study presented at ASH 2019
Dr. Tam, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, tells us about the design of the Phase 2 CAPTIVATE study presented at ASH 2019
Constantine Tam, MBBS, MD, compares the benefits of zanubrutinib to other BTK inhibitors
Dr. Tam, MBBS, MD, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, considers the benefits of zanubrutinib as compared to other second-generation BTK inhibitors in the management of lymphoma
Shyamala Navada, MD, MSCR, discusses the treatment of elderly patients with myeloid malignancies
Dr. Navada, Associate Professor, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai, elaborates on the current approaches to treating elderly patients with myeloid malignancies
Constantine Tam, MBBS, MD, regarding the data that lead to the recent FDA approval of zanubrutinib
Dr. Tam, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, offers his impression of the pivotal clinical data that lead to the recent FDA approval of zanubrutinib
Sattva Neelapu, MD, tells us about the results of the ZUMA-1 study in DLBCL presented at ASH 2019
Dr. Neelapu, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, tells us about the results of the ZUMA-1 study investigating axicabtagene ciloleucel in diffuse large b-cell lymphoma (DLBCL)
Shyamala Navada, MD, MSCR, offers opinion on how the treatment landscape of MDS is evolving
Dr. Navada, Associate Professor, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai, offers opinion on how the treatment of myelodysplastic syndromes (MDS) is changing, especially as a result of the clinical data presented at ASH 2019
Sattva Neelapu, MD, considers whether off-the-shelf CAR-T cell therapy is becoming a reality
Dr. Neelapu, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, considers whether off-the-shelf CAR-T cell therapy is becoming a reality
Constantine Tam, MBBS, MD, offers his impression of the Phase 2 CAPTIVATE study in CLL from ASH '19
Dr. Tam, Consultant Hematologist, Peter MacCallum Cancer Center, Melbourne, Australia, offers his impressions of the Phase 2 CAPTIVATE study investigating the BTK inhibitor ibrutinib plus venetoclax in the 1st line treatment of chronic lymphocytic leukemia (CLL)
Sattva Neelapu, MD, on the role of CAR NK cell therapy in the treatment of B-cell malignancies
Dr. Neelapu, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of off-the-shelf CAR natural killer (CAR NK) cell therapy in the treatment of B-cell malignancies
Shyamala Navada, MD, MSCR, on how oral therapies will impact the treatment of myeloid malignancies
Dr. Navada, MD, Associate Professor, Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mt. Sinai, provides perspective on how oral therapies will impact the treatment landscape of myeloid malignancies
John Burke, MD, regarding tafasitamab or tafasitamab + lenalidomide in addition to R-CHOP in DLBCL
Dr. Burke, Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers, tells us about the design and objectives of the Phase Ib study assessing safety and preliminary efficacy of tafasitamab or tafasitamab plus lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
John Burke, MD, offers opinion on how physicians should be thinking about the use of BTK inhibitors
Dr. Burke, Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers, offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)
Robert Rifkin, MD, FACP, on whether medical oncologists are embracing therapeutic biosimilars
Dr. Rifkin, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, on whether medical oncologists are adopting therapeutic biosimilars in treatment algorithms
John Burke, MD, outlines the patient profile best suited for zanubrutinib in relapsed/refractory MCL
Dr. Burke, Physician, Associate Chair, US Oncology Hematology Research Program, Medical Oncology/ Hematology, Rocky Mountain Cancer Centers, outlines the patient profile best suited for zanubrutinib in relapsed or refractory mantle cell lymphoma (MCL)
Luciano J. Costa, MD, PhD, offers opinion on whether MRD tests can help guide treatment decisions
Dr. Costa, Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, provides opinion on whether minimal residual disease (MRD) tests can be used to help guide treatment decisions
Luciano J. Costa, MD, PhD, explains how academic and community oncologists can utilize MRD tests
Dr. Costa, Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, explains how academic and community oncologists can order a minimal residual disease (MRD) test
Courtney DiNardo, MD, provides opinion on current treatment strategies for elderly AML patients
Dr. DiNardo, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, provides opinion on current treatment strategies for elderly acute myeloid leukemia (AML) patients
Jasmine Zain, MD, shares outcomes from the PRIMO study investigating duvelisib in PTCL
Dr. Zain, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, shares outcomes from the PRIMO study investigating duvelisib in peripheral T-cell lymphoma (PTCL)
Courtney DiNardo, MD, describes the targeted therapy landscape in acute myeloid leukemia
Dr. DiNardo, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, describes the targeted therapy landscape in acute myeloid leukemia (AML) today
Jasmine Zain, MD, tells us about the novel approaches in development for the treatment of PTCL
Dr. Zain, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, tells us about some of the novel approaches in development for the treatment of peripheral T-cell lymphoma (PTCL)
Courtney DiNardo, MD, regarding the evolution of treatment in acute myeloid leukemia
Dr. DiNardo, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, explains how the treatment of acute myeloid leukemia (AML) patients has evolved over the years
Jasmine Zain, MD, discusses the most impressive studies in PTCL presented at ASH 2019
Dr. Zain, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, discusses the most impressive studies in the treatment of peripheral T-cell lymphoma (PTCL) presented at ASH 2019
Courtney DiNardo, MD, considers the role of intensive chemotherapy in newly diagnosed AML
Dr. DiNardo, Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, considers whether intensive chemotherapy should be used upfront to treat newly diagnosed acute myeloid leukemia (AML) patients
Jasmine Zain, MD, considers how peripheral T-cell lymphoma therapy has evolved in recent years
Dr. Zain, Director of the T-cell Lymphoma Program, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center, City of Hope, considers how peripheral T-cell lymphoma (PCL) therapy has evolved in recent years
Max Topp, MD, on whether a risk management plan exists to help reduce toxicity of CAR-T cell therapy
Dr. Topp, Professor and Head of Hematology, University Hospital of Wuerzburg, Germany, on the development of a new risk management plan to potentially reduce the toxicity of CAR-T cell therapy
Bruce Feinberg, DO, elaborates on how oncologists are utilizing real-world evidence today
Dr. Feinberg, Vice President, Clinical Affairs, Chief Medical Officer, Cardinal Health Specialty Solutions, elaborates on how oncologists are utilizing real-world evidence today
John Seymour, MBBS, PHD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL
Dr. Seymour, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, considers whether minimal residual disease (MRD) is a valid endpoint when measuring treatment efficacy in chronic lymphocytic leukemia (CLL)
Bruce Feinberg, DO, provides examples of how RWE has impacted decision-making in oncology
Dr. Feinberg, Vice President, Clinical Affairs, Chief Medical Officer, Cardinal Health Specialty Solutions, provides examples of how real-world evidence (RWE) has impacted decision-making in oncology
John Seymour, MBBS, PHD, elaborates on the updated data from the Phase 3 MURANO trial
Dr. Seymour, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, tells us about the four-year update on the outcomes of the MURANO study, investigating venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)
Bruce Feinberg, DO, defines and explains the role of real-world evidence
Bruce Feinberg, DO, Vice President, Clinical Affairs, Chief Medical Officer, Cardinal Health Specialty Solutions, defines real-world evidence (RWE) and explains how it can be used to aid physicians
Kylee Martens, MD, compares rasburicase versus allopurinol in patients with hyperuricemia
Dr. Martens, Resident Physician, Internal Medicine, University of Washington, compares the effectiveness of rasburicase versus allopurinol in cancer patients with hyperuricemia
Michael Wang, MD, regarding the pivotal clinical data that lead to the FDA approval of zanubrutinib
Dr. Wang, Professor, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, offers his impression of the pivotal clinical data that lead to the FDA approval of zanubrutinib
Michael Wang, MD, speculates on therapies for front-line and relapsed mantle cell lymphoma
Dr. Wang, MD, Professor, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, speculates on therapies for front-line and relapsed mantle cell lymphoma
Michael Wang, MD, on the distinct advantages of zanubrutinib in the management of lymphoma
Dr. Wang, Professor, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, offers his opinion on zanubrutinib as compared to other second-generation BTK inhibitors in the management of lymphoma
Kylee Martens, MD, on the role of rasburicase in managing TLS in patients with renal dysfunction
Dr. Martens, Resident Physician, Internal Medicine, University of Washington, discusses the advantages of rasburicase compared to allopurinol in managing tumor lysis syndrome (TLS) in patients with renal dysfunction
Kylee Martens, MD, on those patient types more suited for treatment with rasburicase vs. allopurinol
Dr. Martens, Resident Physician, Internal Medicine, University of Washington, describes those patient types more suited for treatment with rasburicase versus allopurinol
Max Topp, MD, shares the long-term results of the ZUMA-1 trial presented at ASH 2019
Dr. Topp, Professor and Head of Hematology, University Hospital of Wuerzburg Germany, shares the long-term results of the ZUMA-1 trial presented at ASH 2019
Kylee Martens, MD, considers whether there are certain patient types more prone to TLS
Dr. Martens, Resident Physician, Internal Medicine, University of Washington, considers whether there are particular patient types more prone to tumor lysis syndrome (TLS)
Luciano J. Costa, MD, PhD, on whether minimal residual disease can be used to predict outcomes
Dr. Costa, Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, on whether minimal residual disease (MRD) can be used to predict outcomes
Luciano J. Costa, MD, PhD, on how measurement of MRD is evolving as an endpoint in clinical trials
Dr. Costa, Associate Professor of Medicine, Blood and Marrow Transplantation and Cell Therapy, O’Neal Comprehensive Cancer Center, University of Alabama at Birmingham, explains how measurement of minimal residual disease (MRD) is evolving as an endpoint in clinical trials
Catherine Diefenbach, MD, explains how combination therapies are evolving in follicular lymphoma
Dr. Diefenbach, Director, Clinical Lymphoma Program, Perlmutter Cancer Center at NYU Langone Health, explains how combination therapies are evolving to address the unmet needs in follicular lymphoma
Joseph Alvarnas, MD, on seeking creative solutions to provide proper access to innovative therapy
Dr. Alvarnas, Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics, City of Hope, considers who is getting it right in terms of seeking creative solutions to provide proper access to innovative therapy
Saro Armenian, DO, MPH, reflects on promising clinical innovations in the management of leukemia
Dr. Armenian, Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical Research Hospital, reflects on the most promising clinical innovations in the management of leukemia
Joseph Alvarnas, MD, on the challenges facing cancer centers when delivering innovative therapies
Dr. Alvarnas, Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics, City of Hope, discusses the challenges facing cancer centers when delivering innovative therapies
Saro Armenian, DO, MPH, considers the relevance of bone marrow transplant in leukemia & lymphoma
Dr. Armenian, Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical Research Hospital, considers the relevance of bone marrow transplant with the emergence of innovative targeted therapies
Catherine Diefenbach, MD, regarding the unmet needs in the management of follicular lymphoma
Dr. Diefenbach, Director, Clinical Lymphoma Program, Perlmutter Cancer Center at NYU Langone Health, provides opinion on the unmet needs in the management of follicular lymphoma
Saro Armenian, DO, MPH, on bone marrow transplant survivorship outcomes in AML patients
Dr. Armenian, Pediatric Hematologist/Oncologist, Associate Professor, Departments of Pediatrics and Population Sciences, City of Hope Helford Clinical Research Hospital, on bone marrow transplant survivorship outcomes in adult acute myeloid leukemia (AML) patients
Michael Wang, MD, shares details from the ZUMA-2 trial in mantle cell lymphoma presented at ASH 2019
Dr. Wang, Professor, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, elaborates on the ZUMA-2 trial investigating anti-CD19 CAR-T cell therapy in mantle cell lymphoma
Joseph Alvarnas, MD, regarding CAR-T cell therapy in an era of value-based care
Dr. Alvarnas, Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics, City of Hope, shares his philosophy regarding CAR-T cell therapy in an era of value-based care
Catherine Diefenbach, MD, on the recent data investigating obinutuzumab in follicular lymphoma
Dr. Diefenbach, Director, Clinical Lymphoma Program, Perlmutter Cancer Center at NYU Langone Health, tells us about the design and outcomes of the Phase 1/2 study investigating obinutuzumab in relapsed/refractory follicular lymphoma from ASH 2019
Joseph Alvarnas, MD, on how to responsibly integrate clinical innovations into treatment algorithms
Dr. Alvarnas, Vice President of Government Affairs, Senior Medical Director for Employer Strategy, Director of Value Based Analytics, City of Hope, explains how to responsibly integrate clinical innovations into treatment algorithms
Michael Jain, MD, offers his opinion on off-the-shelf CAR-T cell therapy
Dr. Jain, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, offers his opinion on off-the-shelf CAR-T cell therapy
James McCloskey, MD, regarding the QUASAR-001 study presented at ASH 2019
James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains the design and outcomes of the QUASAR-001 study in acute myeloid leukemia (AML) presented at ASH 2019
Michael Jain, MD, shares the outcomes of the US CAR-T Cell Consortium study from ASH 2019
Dr. Jain, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, tells us about the outcomes of the US CAR-T Cell Consortium study investigating bridging therapy prior to delivery of CAR-T cell therapy
James McCloskey, MD, considers how the role of molecular profiling in AML is changing
Dr. McCloskey, Interim Chief, Division of Leukemia, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us how the role of molecular profiling is changing in acute myeloid leukemia (AML) as a result of the data from ASH 2019.
Michael Jain, MD, discusses how population-based outcomes in B-cell lymphomas are changing
Dr. Jain, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, discusses how population-based outcomes in B-cell lymphomas are changing
James McCloskey, MD, speculates on the landscape of MDS as a result of data presented at ASH '19
Dr. McCloskey, Interim Chief, Division of Leukemia, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how the treatment of myelodysplastic syndromes (MDS) is changing as a result of clinical data presented at ASH 2019
Michael Jain, MD, offers perspective on the latest treatment trends for aggressive lymphomas
Dr. Jain, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, offers perspective on the latest treatment trends for aggressive lymphomas
James McCloskey, MD, shares his impression of the Phase 3 ASCERTAIN trial in MDS
Dr. McCloskey, Interim Chief, Division of Leukemia, John Theurer Cancer Center, Part of Hackensack University Medical Center, shares his impression of the Phase 3 ASCERTAIN study investigating cedazuridine and decitabine versus decitabine in myelodysplastic syndromes (MDS)
Michael Jain, MD, regarding CAR-natural killer (NK) cell therapy
Dr. Jain, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, regarding off-the-shelf CAR-natural killer (NK) cell therapy in the treatment of B-cell malignancies
Lori Leslie, MD, on real-world evidence regarding CAR-T cell therapy in lymphoma
Dr. Leslie, MD, Medical Oncologist, Regional Cancer Care Associates, offers her thoughts on the real-world evidence presented at ASH 2019 regarding CAR-T cell therapy in lymphoma
Lori Leslie, MD, offers perspective on the role of umbralisib in relapsed/refractory lymphoma
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, offers perspective on the role of umbralisib in the management of relapsed/refractory lymphoma
John Mascarenhas, MD, on JAK inhibitors & combination therapies in myeloproliferative neoplasms
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, elaborates on JAK inhibitors and combination therapies in the treatment of myeloproliferative neoplasms
Lori Leslie, MD, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, considers the use of zanubrutinib in relapsed/refractory mantle cell lymphoma
John Mascarenhas, MD, on the role of molecular analysis in myeloproliferative neoplasms
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, on whether molecular analysis is appropriate and helpful in determining treatment approaches for myeloproliferative neoplasms
Lori Leslie, MD, considers how physicians should be thinking about the use of BTK inhibitors in CLL
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, considers how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)
John Mascarenhas, MD, on the individualized management of myeloproliferative neoplasms
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, tells us about his approach to the individualized management of myeloproliferative neoplasms
Lori Leslie, MD, offers her perspective on the latest treatment trends in aggressive lymphomas
Dr. Leslie, Medical Oncologist, Regional Cancer Care Associates, offers her perspective on the latest treatment trends in Burkitt lymphoma and other aggressive lymphomas
John Mascarenhas, MD, shares outcomes from the MANIFEST study examining CPI-0610 in myelofibrosis
Dr. Mascarenhas, Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, shares outcomes from the MANIFEST study investigating CPI-0610 as a monotherapy or add-on to ruxolitinib in patients with myelofibrosis
Joshua Richter, MD, discusses the data investigating iberdomide presented at ASH 2019
Dr. Richter, Assistant Professor, Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mt. Sinai School of Medicine, discusses the data investigating iberdomide presented at ASH 2019
Joshua Richter, MD, regarding the Phase 3 CANDOR study in relapsed/refractory multiple myeloma
Dr. Richter, Assistant Professor, Division of Hematology and Medical Oncology, The Tisch Cancer Institute, Mt. Sinai School of Medicine, tells us about the design and outcomes of the Phase 3 CANDOR study in relapsed/refractory multiple myeloma
Leslie Popplewell, MD, summarizes the role of checkpoint inhibitors in the treatment of lymphomas
Dr. Popplewell, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope, summarizes the role of checkpoint inhibitors in the treatment of lymphomas as presented at ASH 2019
Catherine Smith, MD, discusses prognostic factors and outcomes in acute myeloid leukemia
Dr. Smith, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, UCSF, discusses the prognostic factors in acute myeloid leukemia (AML) and how these factors relate to outcomes for patients
Leslie Popplewell, MD, on the role of CAR-T cell therapy in aggressive B-cell lymphomas
Dr. Popplewell, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope, shares her thoughts on the role of CAR-T cell therapy in the treatment of aggressive B-cell lymphomas
Catherine Smith, MD, offers her overall impression on the changing FLT3 inhibition landscape in AML
Dr. Smith, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, UCSF, offers her overall impression on the changing FLT3 inhibition landscape in acute myeloid leukemia (AML)
Leslie Popplewell, MD, considers the use of CAR-T cell therapies in aggressive B-cell lymphomas
Dr. Popplewell, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope, discusses clinical evidence supporting the use of CAR-T cell therapies in the treatment of aggressive B-cell lymphomas
Catherine Smith, MD, on whether all acute myeloid leukemia patients should be tested for FLT3
Dr. Smith, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, UCSF, on whether all acute myeloid leukemia (AML) patients should be tested for FLT3
Leslie Popplewell, MD, considers whether there is sufficient evidence supporting bridging therapy
Dr. Popplewell, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope, considers whether there is sufficient evidence to use bridging therapy before CAR-T therapy
Catherine Smith, MD, tells us about the outcomes of the Phase 3 ADMIRAL trial presented at ASH 2019
Dr. Smith, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, UCSF, tells us about the outcomes of the Phase 3 ADMIRAL trial and why it is important to the management of acute myeloid leukemia
Leslie Popplewell, MD, offers opinion on the next frontier in the development of CAR-T treatment
Dr. Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope, offers opinion on the next frontier in the development of CAR-T treatment strategies
Carol Moreno, MD, PhD, on the Phase 3 trial examining ibrutinib + rituximab versus FCR in CLL
Dr. Moreno, Hematologist, Autonomous University of Barcelona, describes the outcomes of the Phase 3 study investigating 1st line ibrutinib and rituximab versus FCR in younger chronic lymphocytic leukemia (CLL) patients presented at the 2018 ASH Annual Meeting and Exposition
Carol Moreno, MD, PhD, on how the outcomes of the illUMINTATE trial impact treatment of CLL
Dr. Moreno, Hematologist, Autonomous University of Barcelona, offers opinion on whether the outcomes of the illUMINTATE trial change the way 1st line chronic lymphocytic leukemia (CLL) is treated today
Jasmine Zain, MD, on the most exciting studies in lymphoma presented at ASH 2018
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, shares details of the most exciting studies in lymphoma presented at the 2018 ASH Annual Meeting and Exposition
Yana Pikman, MD, regarding research outcomes from the LEAP Consortium
Dr. Pikman, Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Children’s Hospital, explains how the results of the LEAP Consortium’s clinical study may help identify mutations that can improve outcomes in pediatric acute leukemia
Jasmine Zain, MD, discusses novel treatment research regarding transplants at City of Hope
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses novel treatment research regarding transplants
Jasmine Zain, MD, considers the impact of the new induction regimen in PTCL
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, provides opinion on whether the standard of care in the treatment of peripheral T-cell lymphoma (PTCL) is changing as a result of the new induction regimen
Yana Pikman, MD, on the efforts of the LEAP Consortium in pediatric acute leukemia
Dr. Pikman, Instructor in Pediatrics, Dana Farber Cancer Institute, Boston Children’s Hospital, explains the LEAP Consortium and how the group is developing actionable genomic targets in pediatric acute leukemia
Jasmine Zain, MD, defines successful induction regimens when treating PTCL
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, discusses what contributes to a successful induction regimen when treating peripheral T-cell lymphoma (PTCL) patients
Jasmine Zain, MD, elaborates on the investigation of novel induction regimens in PTCL
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, tells us about the investigation of novel induction regimens prior to ASCT for the treatment of peripheral T-cell lymphoma (PTCL)
Jasmine Zain, MD, regarding the standard of care in treatment of PTCL
Dr. Zain, Associate Clinical Professor of Hematology & Hematopoietic Cell Transplantation, Director, T cell Lymphoma Program, City of Hope, explains how has the standard of care in the treatment of peripheral T-cell lymphoma (PTCL) has changed in the last several years
Rod A. Humerickhouse, MD, PhD, describes recent advancements in the treatment of CLL
Dr. Humerickhouse, Group Project Leader, Oncology Development, AbbVie, describes recent advancements in the treatment of chronic lymphocytic leukemia (CLL)
Rod A. Humerickhouse, MD, PhD, considers testing for minimal residual disease in CLL
Dr. Humerickhouse, Group Project Leader, Oncology Development, AbbVie, elaborates on whether chronic lymphocytic leukemia (CLL) patients should be tested for minimal residual disease (MRD)
Rod A. Humerickhouse, MD, PhD, on MRD as a surrogate marker in chronic lymphocytic leukemia
Dr. Humerickhouse, Group Project Leader, Oncology Development, AbbVie, provides opinion on whether minimal residual disease (MRD) is a legitimate surrogate marker for response and risk of recurrence in chronic lymphocytic leukemia (CLL)
Jason Butler, PhD, considers how vascular integrity impacts the leukemia-initiating metabolic switch
Dr. Butler, Associate Scientist, Regenerative Medicine and Associate Professor, Center for Discovery and Innovation, Hackensack University, discusses how vascular integrity impacts the leukemia-initiating metabolic switch
Rena Feinman, PhD, considers the the role of the microbiome in cancer & response to therapy
Dr. Feinman, Associate Scientist, Department of Research, John Theurer Cancer Center at Hackensack University Medical Center, explains why is there such an interest in the role of the microbiome in cancer and response to therapy
Jason Butler, PhD, on how age-associated aberrant MAPK signaling impacts hematopoiesis
Dr. Butler, Associate Scientist, Regenerative Medicine and Associate Professor, Center for Discovery and Innovation, Hackensack University, shares how age-associated aberrant MAPK signaling impacts hematopoiesis
Rod A. Humerickhouse, MD, PhD, regarding potential side effects from venetoclax + rituximab in CLL
Dr. Humerickhouse, Group Project Leader, Oncology Development, AbbVie, elaborates on potential concerns regarding side effects when treating chronic lymphocytic leukemia (CLL) patients with combination venetoclax and rituximab
Sen Zhuang, MD, PhD, shares the research & development philosophy at Janssen
Dr. Zhuang, VP, Oncology Clinical Research, Janssen, tells us about the research and development philosophy at Janssen Oncology Clinical Research
Rod A. Humerickhouse, MD, PhD, on treating CLL patients with venetoclax and rituximab
Dr. Humerickhouse, Group Project Leader, Oncology Development, AbbVie, tells us about the long-term outcomes when treating chronic lymphocytic leukemia (CLL) patients with venetoclax and rituximab
Keith Pratz, MD, considers emerging therapies for newly diagnosed or relapsed AML patients
Dr. Pratz, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses emerging therapies for newly diagnosed or relapsed acute myelogenous leukemia (AML) patients
Sattva Neelapu, MD, speculates on the future of CAR-T therapies in lymphoma
Dr. Neelapu, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, speculates on the future of CAR-T therapy in the treatment of lymphoma
Keith Pratz, MD, on genetic testing in AML prior to the start of therapy
Dr. Pratz, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, considers whether all newly diagnosed acute myeloid leukemia (AML) patients should undergo genetic testing prior to the start of therapy
Carol Moreno, MD, PhD, discusses MRD as a legitimate surrogate marker in CLL
Dr. Moreno, Hematologist, Autonomous University of Barcelona, considers whether minimal residual disease (MRD) is a legitimate surrogate marker for response and risk of recurrence when treating chronic lymphocytic leukemia (CLL)
Carol Moreno, MD, PhD, describes recent advancements in the treatment of CLL
Dr. Moreno, Hematologist, Autonomous University of Barcelona, elaborates on recent advancements in the treatment of chronic lymphocytic leukemia (CLL)
Keith Pratz, MD, comments on the Phase I study of gilteritinib presented at ASH 2018
Dr. Pratz, Assistant Professor of Oncology, Sidney Kimmel, Comprehensive Cancer Center, Johns Hopkins University, comments on the Phase I study of gilteritinib in combination with induction and consolidation therapy in subjects with newly diagnosed acute myelogenous leukemia (AML)
Carol Moreno, MD, PhD, shares outcomes from the iLLUMINATE trial presented at ASH 2018
Dr. Moreno, Hematologist, Autonomous University of Barcelona, tells us about the outcomes of the Phase 3 iLLUMINATE trial investigating ibrutinib plus obinutuzumab for 1st line therapy of chronic lymphocytic leukemia (CLL)
Sattva Neelapu, MD, considers the use of axicabtagene ciloleucel with elderly lymphoma patients
Dr. Neelapu, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, discusses whether it is safe to use axicabtagene ciloleucel with elderly lymphoma patients
Keith Pratz, MD, regarding the reliability of the companion diagnostic test for FLT3
Dr. Pratz, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, provides opinion on the reliability of the companion diagnostic test for FLT3 and whether he feels comfortable using the test to determine a course of treatment in acute myelogenous leukemia (AML)
Sattva Neelapu, MD, on real-world experience & clinical studies examining axicabtagene ciloleucel
Dr. Neelapu, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, elaborates on how the real-world experience with axicabtagene ciloleucel compares with the previously published clinical studies of axicabtagene ciloleucel as shown in Abstract 91 at the 2018 ASH Annual Meeting and Exposition
Keith Pratz, MD, describes how gilteritinib fits into treatment algorithms for AML
Dr. Pratz, Assistant Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, discusses how newly approved gilteritinib will be incorporated into treatment plans for acute myelogenous leukemia (AML)
Sattva Neelapu, MD, regarding the ZUMA-1 two-year follow-up study in DLBCL
Dr. Neelapu, Department of Lymphoma and Myeloma, Division of Cancer Medicines, MD Anderson Cancer Center, tells us about the ZUMA-1 two-year follow-up study of axicabtagene ciloleucel in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) patients presented at the 2018 ASH Annual Meeting and Exposition
James McCloskey, MD, elaborates on the role of molecular testing in newly diagnosed AML
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, considers whether most hematologists and oncologists are aware that molecular tests are appropriate for newly diagnosed acute myelogenous leukemia (AML) patients
James McCloskey, MD, regarding molecular testing in acute myelogenous leukemia
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, elaborates on how molecular tests are impacting treatment decisions for acute myelogenous leukemia (AML) patients
James McCloskey, MD, considers the application of the FLT3 test in newly diagnosed AML patients
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, provides opinion on whether the FLT3 test may be applied in newly diagnosed acute myelogenous leukemia (AML)
James McCloskey, MD, describes how the FLT3 mutation influences treatment decisions in AML
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, discusses how the FLT3 mutation influences treatment plans for acute myelogenous leukemia (AML)
James McCloskey, MD, speculates on the reliability of the companion diagnostic test for FLT3
Dr. McCloskey, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, provides opinion on the reliability of the companion diagnostic test for FLT3 and whether the test may be used to determine treatment in acute myelogenous leukemia (AML)
Edward Copelan, MD, regarding gilteritinib for patients with FLT3+ AML
Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, on how he is currently testing acute myelogenous leukemia (AML) and how he will incorporate newly approved gilteritinib for patients with AML that are FLT3+
John Burke, MD, elaborates on the Beat AML umbrella study
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, tells us about the design, outcomes and significance of the Beat AML umbrella study
John Burke, MD, comments on clinical research examining gilteritinib in newly diagnosed AML
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, comments on the Phase I study of gilteritinib in combination with induction and consolidation therapy in subjects with newly diagnosed acute myeloid leukemia (AML)
John Burke, MD, elaborates on the incorporation of venetoclax into AML treatment regimens
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, explains how he plans to incorporate venetoclax into treatment regimen for acute myeloid leukemia (AML) patients
Elizabeth Budde, MD, evaluates the clinical study investigating mosunetuzumab from ASH 2018
Dr. Budde, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, tells us about the results of the clinical study investigating mosunetuzumab, an anti-CD20/CD3 monoclonal antibody, in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL) patients
John Burke, MD, speaks to the reliability of the FLT3 mutation test
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, considers whether the companion diagnostic test for FLT3 is reliable in determining a course of treatment in acute myelogenous leukemia (AML)
Elizabeth Budde, MD, on how City of Hope has overcome logistical hurdles associated with CAR-T
Dr. Budde, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, explains how her organization has overcome some of the logistical hurdles associated with CAR-T therapies
John Burke, MD, regarding gilteritinib in acute myeloid leukemia treatment
Dr. Burke, Hematologist/Oncologist and Associate Chair of the US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, elaborates on how newly approved gilteritinib will fit into treatment algorithms for patients with acute myeloid leukemia (AML)
Elizabeth Budde, MD, discusses the role of CAR-T therapies in lymphoma treatment algorithms
Dr. Budde, Assistant Professor in the Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, provides opinion on how CAR-T therapies are being incorporated into treatment algorithms for lymphoma
Robert Rifkin, MD, shares his thoughts on if a rituximab biosimilar can replace rituximab
Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, shares his thoughts on if a rituximab biosimilar can replace rituximab in follicular lymphoma treatment regimens and beyond
Robert Rifkin, MD, discusses the rationale for genetically profiling AML patients
Dr. Rifkin, Hematologist/Oncologist, Associate Chair, US Oncology Hematology Research, Rocky Mountain Cancer Centers, discusses the rationale for genetically profiling Acute Myelogenous Leukemia (AML) patients, which patients should be profiled, and how actionable the results are
Ravi Vij, MD, on molecular testing and acute myelogenous leukemia
Dr. Vij, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, describes how molecular tests are being incorporated into acute myelogenous leukemia (AML) treatment algorithms
Samer Khaled, MD, tells us about the MEDALIST study examining myelodysplastic syndrome
Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, describes the results of the MEDALIST study and how it will impact the way anemia is treated in myelodysplastic syndrome (MDS) patients
Samer Khaled, MD, on incorporating venetoclax into treatment regimens for AML
Dr. Khaled, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, on incorporating venetoclax into treatment regimens for acute myeloid leukemia (AML) patients
Ravi Vij, MD, shares details regarding his clinical study presented at ASH 2018
Dr. Vij, Professor of Medicine, Oncology Division, Bone Marrow Transplantation & Leukemia, Washington University School of Medicine, tells us about the outcomes of his study investigating ixazomib, revlimid, and dexamethasone consolidation
Samer Khaled, MD, regarding gilteritinib in treatment of acute myelogenous leukemia
Dr. Khaled, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, considers how he will use newly FDA approved Xospata (gilteritinib) for patients with acute myelogenous leukemia (AML)
Samer Khaled, MD, shares details of his study examining the use of CAR-T therapy in ALL
Dr. Khaled, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, tells us about the outcomes of his study examining the use of CAR-T therapy in acute lymphoblastic leukemia (ALL) at the ASH 2018 Annual Meeting and Exposition
Chadi Nabhan, MD, MBA, on the role of advanced practice practitioners
Dr. Nabhan, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses the role of advanced practice practitioners and why they are often challenging to recruit and retain
Chadi Nabhan, MD, MBA, shares what is being done to prevent oncologist burnout
Dr. Nabhan, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, tells us what is being done to prevent oncologist burnout and make the field more attractive to new recruits
Chadi Nabhan, MD, MBA, discusses the key factors contributing to physician burnout
Dr. Nabhan, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, shares the primary driving factors contributing to physician burnout
Chadi Nabhan, MD, MBA, regarding the risks related to two-sided payment agreements
Dr. Nabhan, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, discusses the potential risks faced by oncologists if they enter into a two-sided payment agreement with CMS
Chadi Nabhan, MD, MBA, elaborates on the skepticism regarding MACRA
Dr. Nabhan, VP, Chief Medical Officer, Cardinal Health Specialty Solutions, considers why oncologists remain skeptical about the overall benefits of MACRA
Jeff Sharman, MD, shares his thoughts on rituximab biosimilars in follicular lymphoma
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, shares his thoughts on if a rituximab biosimilar can replace rituximab in follicular lymphoma treatment regimens and beyond
Lorenz Trumper, MD, discusses the results of ECHELON-2 in frontline PTCL
Dr. Trumper, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Göttingen, discusses the results of ECHELON-2 and whether the results will change the way frontline peripheral T-cell lymphoma (PTCL) patients will be treated
Jeff Sharman, MD, on the outcomes of CAPTIVATE study investigating ibrutinib and venetoclax
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, on the outcomes of the CAPTIVATE study investigating ibrutinib and venetoclax in the treatment of front line Chronic Lymphocytic Leukemia (CLL)
Jeff Sharman, MD, on how important the CLL-14 study is in determining CLL treatment strategies
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, explains how important the CLL-14 study is in determining Chronic Lymphocytic Leukemia (CLL) treatment strategies
Lorenz Trumper, MD, on the current standard of care for the frontline treatment of PTCL
Dr. Trumper, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Göttingen, discusses what the current standard of care for the frontline treatment of patients with peripheral T-cell lymphoma (PTCL)
Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in younger CLL patients
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, about the outcomes of the phase 3 study presented here at ASH investigating 1st line ibrutinib + rituximab versus FCR in younger Chronic Lymphocytic Leukemia (CLL) patients
Lorenz Trumper, MD, speaks on the differences between B-Cell and T-Cell lymphomas
Dr. Trumper, Professor of Internal Medicine and Chairman of the Department of Hematology and Oncology, Georg August University of Göttingen, speaks on the differences between B-Cell and T-Cell lymphomas and what drives the design of clinical trials
Jeff Sharman, MD, discusses the phase 3 study investigating ibrutinib in older CLL patients
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, tells us about the outcomes of the phase 3 study presented here at ASH investigating 1st line ibrutinib +/- rituximab versus bendamustine plus rituximab in older Chronic Lymphocytic Leukemia (CLL) patients
Swaminathan P. Iyer, MD, regarding improvements in the treatment of CTCL
Dr. Iyer, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, discusses improvements being made in the treatment of cutaneous T-cell lymphoma (CTCL)
Swaminathan P. Iyer, MD, shares exciting studies regarding the treatment of PTCL from ASH 2018
Dr. Iyer, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, offers opinion on impressive studies regarding the treatment of peripheral T-cell lymphoma (PTCL) presented at the 2018 ASH Annual Meeting and Exposition
Swaminathan P. Iyer, MD, on the outcomes of the ECHELON-2 study in PTCL
Dr. Iyer, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine Division, MD Anderson Cancer Center, tells us about the study design and outcomes of the ECHELON-2 study in peripheral T-cell lymphoma (PTCL)
Andre Goy, MD, comments on the long-term outcome of acalabrutinib in MCL
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, discusses the long-term outcomes of acalabrutinib in mantle cell lymphoma (MCL)
Andre Goy, MD, on immunotherapy and the treatment of hematologic malignancies
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, explains how immunotherapies are being integrated into the treatment of hematologic malignancies
Andre Goy, MD, considers checkpoint inhibitors in hematologic malignancies
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, elaborates on whether checkpoint inhibitors (i.e. ipilimumab and nivolumab) can be used as consolidation following ASCT in hematologic malignancies
Andre Goy, MD, discusses his real-world experience using axi-cel CAR-T cell therapy
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, offers opinion on his real-world experience using axicabtagene ciloleucel (axi-cel) CAR-T cell therapy to treat lymphoma
Andre Goy, MD, on research regarding the use of axi-cel CAR-T cell therapy in DLBCL
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, elaborates on the design and outcomes of a study looking at the use of axicabtagene ciloleucel (axi-cel) CAR-T cell therapy for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) presented at the ASH 2018 Annual Meeting and Exposition
Tatyana Feldman, MD, regarding improvements in the treatment of CTCL
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, discusses improvements in the treatment of cutaneous T-cell lymphoma (CTCL) from the 2018 ASH Annual Meeting and Exposition
Tatyana Feldman, MD, on exciting studies from ASH 2018 regarding the treatment of PTCL
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, provides opinion on impressive studies regarding the treatment of peripheral T-cell lymphoma (PTCL) presented at the 2018 ASH Annual Meeting and Exposition
Frederick Locke, MD, on whether CAR-T therapies will be expanded into solid tumors
Dr. Locke, Program Co-Leader, Immunology Moffitt Cancer Center, shares his thoughts on whether CAR-T therapies will be expanded into solid tumors
Frederick Locke, MD, on the management of toxicity withs with CAR-T therapies
Dr. Locke, Program Co-Leader, Immunology Moffitt Cancer Center, discusses how to manage toxicities with CAR-T therapies
Julie Vose, MD, on management of common toxicities with CAR-T therapies
Dr. Vose, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, talks about the most common toxicities associated with CAR-T therapies and how to manage them
Julie Vose, MD, discusses improvements made in the delivery of CAR-T therapies in lymphoma
Dr. Vose, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses what improvements are being made to the delivery of CAR-T therapies to improve outcomes in the treatment of lymphoma
Frederick Locke, MD, on what improvements to turn around time with CAR-T therapies
Dr. Locke, Program Co-Leader, Immunology Moffitt Cancer Center, on what improvements to turn around time Moffitt has implemented to help make CAR-T therapies more convenient and effective
Frederick Locke, MD, discusses how to integrate CAR-T with stem cell transplant
DR. Locke, Program Co-Leader, Immunology Moffitt Cancer Center, discusses how to integrate CAR-T with stem cell transplant and therapeutic combinations to treat lymphoma in the future
Andre Goy, MD, on responses & outcomes when treating lymphoma with CAR-T therapies
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, provides opinion on the responses and outcomes when treating lymphoma with CAR-T therapies and whether they will become a significant part of the treatment regimens
Tatyana Feldman, MD, shares outcomes of the ECHELON-2 study in PTCL
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, tell us about the study design and outcomes of the ECHELON-2 study in peripheral T-cell lymphoma (PTCL)
Tatyana Feldman, MD, offers opinion on the ECHELON-2 study in PTCL
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, speculates on whether the ECHELON-2 study is game-changing for patients with peripheral T-cell lymphoma (PTCL)
Frederick Locke, MD, on the use of CAR-T therapies in leukemia and lymphoma
Dr. Locke, Program Co-Leader, Immunology Moffitt Cancer Center, shares his thoughts on whether CAR-T therapies are showing impressive results in leukemia and lymphoma, and if real world evidence is matching up well with clinical trial results
Tatyana Feldman, MD, on unmet needs in peripheral T-cell lymphoma (PTCL)
Dr. Feldman, Hematology & Oncology, Hackensack University Medical Center, John Theurer Cancer Center, describes unmet needs in the treatment of peripheral T-cell lymphoma (PTCL)
Julie Vose, MD, on if CAR-T therapies are showing impressive results in lymphoma
Dr. Vose, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, explains if CAR-T therapies are showing impressive results in lymphoma, and whether real world evidence is matching up well with clinical trial results
Julie Vose, MD, tells us about the results of the AUGMENT study in relapsed/refractory indolent NHL
Dr. Vose, Professor, Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, tells us about the results of the AUGMENT study looking at lenalidomide and rituximab in the treatment of relapsed/refractory indolent Non-Hodgkin’s Lymphoma (NHL)
Julie Vose, MD, discusses whether polatuzumab improves outcomes in DLBCL patients
Dr. Vose, Professor Internal Medicine Division of Oncology & Hematology University of Nebraska Medical Center, discusses whether adding polatuzumab to bendamustine and rituximab improve outcomes in diffuse large B-cell lymphoma (DLBCL) patients
Andre Goy, MD, discusses how CAR-T therapies are being integrated into the treatment of large B-Cell lymphoma
Dr. Goy, Chairman and Director of John Theurer Cancer Center, Chief of the Division of Lymphoma, Hackensack University Medical Center, discusses how CAR-T therapies are being integrated into the treatment of relapsed/refractory large B-Cell lymphoma
Swaminathan Padmanabhan Iyer, MD, on if ECHELON-2 study is game changing for patients with PTCL
Dr. Iyer, Professor, Department of Lymphoma and Myeloma, MD Anderson Cancer Center, on if ECHELON-2 study is game changing for patients with Peripheral T-Cell Lymphoma (PTCL)
Keith Pratz, MD, discusses venetoclax in treatment of acute myeloid leukemia (AML)
Dr. Pratz, Assistant Professor of Oncology , Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, shares how he plans to incorporate venetoclax into treatment regimens for acute myeloid leukemia (AML) patients
James McClosky, MD, on using newly FDA approved gilteritinib for patients with AML
Dr. McClosky, Interim Chief, Division of Leukemia, Hackensack University Medical Center, John Theurer Cancer Center, on using newly FDA approved gilteritinib for patients with AML
Daniel J. DeAngelo, MD, PhD, offers his opinion on the clinical development of BLU-285
Dr. DeAngelo elaborates on the clinical development of BLU-285 moving forward
Daniel J. DeAngelo, MD, PhD, on the phase 1 study of BLU-285 in advanced systemic mastocytosis
Dr. DeAngelo expands on the outcomes from the phase 1 study of BLU-285 in advanced systemic mastocytosis
Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of BLU-285 and what makes it unique
Dr. DeAngelo provides the mechanism of action of BLU-285 and explains what makes it unique and promising
Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML
Dr. Lane elaborates on the efficacy outcomes of SL-401 consolidation therapy in patients with acute myeloid leukemia (AML)
Robert Soiffer, MD, discusses ways to enhance the activity of Il-2 in chronic GVHD
Dr. Soiffer discusses ways to enhance the activity of Il-2 in chronic graft versus host disease (GVHD)
Ching-Hon Pui, MD, speculates on the use of CAR T-cell therapy in pediatric ALL patients
Dr. Pui tells us how he sees CAR T-cell therapy being used in pediatric acute lymphocytic leukemia (ALL) patients
Ching-Hon Pui, MD, explains how precision medicine is changing the way pediatric ALL is treated
Dr. Pui describes how precision medicine is changing the way we treat pediatric acute lymphocytic leukemia (ALL) today
Ching-Hon Pui, MD, on whether the FDA should accept minimal residual disease as a surrogate endpoint
Dr. Pui offers opinion on whether the FDA should accept minimal residual disease as a surrogate endpoint for regulatory approval
Ching-Hon Pui, MD, discusses minimal residual disease in pediatric and adult ALL patients
Dr. Pui elaborates on the optimal way to use minimal residual disease in pediatric and adult acute lymphocytic leukemia (ALL) patients
Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment
Dr. Cortes tells us about the clinical data presented at ASH 2017 regarding treatment of front-line chronic myelogenous leukemia (CML) with bosutinib
Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL
Dr. Kahl elaborates on the evidence for using rituximab maintenance as a front-line treatment option with bendamustine-rituxan in follicular lymphoma (FL) patients
James R. Downing, MD, explains the mission of St. Jude Children’s Research Hospital
Dr. Downing shares how the mission of St. St. Jude Children’s Research Hospital is benefiting the pediatric cancer patient community
Andrew Lane, MD, PhD, on how frequently clinicians interact with frail AML patients
Dr. Lane describes how often clinicians will see frail acute myeloid leukemia (AML) patients and how this patient population should be managed
Andrew Lane, MD, PhD, on treatment approaches when managing frail AML patients
Dr. Lane offers his opinion on agents or treatment approaches a clinician should seek when managing frail acute myeloid leukemia (AML) patients
Andrew Lane, MD, PhD, offers strategies for clinicians when treating frail AML patient populations
Dr. Lane discusses strategies for frail acute myeloid leukemia (AML) patients who do not qualify for intensive therapy
Andrew Lane, MD, PhD, shares outcomes from the phase 2 study of SL-401 in patients with BPDCN
Dr. Lane discusses the outcomes from the pivotal phase 2 study of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN)
Jesus San-Miguel, MD, on daratumumab in a first-line setting as a result of the ALCYON study
Dr. San-Miguel shares his thoughts on whether daratumumab should be adopted in the first-line setting outside of the U.S. as a result of the ALCYON study
Jesus San-Miguel, MD, explains the efficacy and safety outcomes of the ALCYON clinical study
Dr. San-Miguel elaborates on the efficacy and safety outcomes of the ALCYON clinical study
Jens G. Lohr, MD, PhD, discusses the kind of information we can gather from liquid biopsy
Dr. Lohr elaborates on the kind of information we can get from liquid biopsy and how this compares to the information we can gather from bone marrow biopsy
Jens G. Lohr, MD, PhD, on utilizing liquid biopsy and how it compares to bone marrow biopsy
Dr. Lohr explains why we should use liquid biopsy and how it compares to bone marrow biopsy
James Essell, MD, discusses the concerns for patients receiving allogeneic transplantations
Dr. Essell elaborates on the conners for patients receiving allogeneic transplantations today
James Essell, MD, on how allogeneic transplantation is incorporated into hematologic malignancy
Dr. Essell explains how allogeneic transplantation is incorporated into hematologic malignancy today
Brad S. Kahl, MD, considers the unmet medical needs in treatment of Hodgkin lymphoma
Dr. Kahl offers his opinion on the unmet needs in Hodgkin lymphoma
Brad S. Kahl, MD, discusses the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma
Dr. Kahl shares information on the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma presented at ASH 2017
Brad S. Kahl, MD, tells us about his study evaluating ADCT-402 in DLBCL
Dr. Kahl elaborates on his study evaluating ADCT-402 in diffuse large B-cell lymphoma (DLBCL)
Jorge Cortes, MD, on how generic imatinib is being adopted as an alternative to branded imatinib
Dr. Cortes elaborates on how generic imatinib is being adopted in clinical studies as an alternative to branded imatinib
Jorge Cortes, MD, on what was discussed at ASH 2017 regarding treatment discontinuation in AML
Dr. Cortes shares what was talked about at ASH 2017 regarding treatment discontinuation in acute myeloid leukemia (AML) patients
Simon Rule, MD, considers the clinical development plan with Imbruvica in mantle cell lymphoma (MCL)
Dr. Rule shares his thoughts on the clinical development plan with Imbruvica (ibrutinib) in mantle cell lymphoma (MCL)
Simon Rule, MD, discusses the ibrutinib data in relapsed/refractory MCL presented at ASH 2017
Dr. Rule tells us about the presentation of the ibrutinib data in relapsed/refractory mantle cell lymphoma (MCL) presented at ASH 2017
Edward A. Copelan, MD, shares highlights from ASH 2017 regarding treatment of acute myeloid leukemia
Dr. Copelan offers his opinion on the highlights presented at ASH 2017 in the treatment of acute myeloid leukemia (AML)
Edward A. Copelan, MD, considers whether azacitidine can be used for induction in AML
Dr. Copelan on whether azacitidine can be used for induction in acute myeloid leukemia (AML)
James R. Downing, MD, discusses the significant studies presented at ASH 2017
Dr. Downing considers the significant clinical studies performed by physicians at St. Jude Children’s Research Hospital and presented at ASH 2017
James R. Downing, MD, on the evolution of St. Jude Children’s Research Hospital
Dr. Downing shares how St. Jude Children’s Research Hospital has been evolving to better meet the needs of pediatric cancer patients
John Burke, MD, on rituximab as an effective strategy after 1st line bendamustine-rituximab in FL
Dr. Burke, on whether rituximab is an effective maintenance strategy after 1st line bendamustine-rituximab in previously untreated follicular lymphoma patients
Keith Pratz, MD, on the proportion of AML patients who fall into the frail category
Dr. Pratz describes the proportion of acute myeloid leukemia (AML) patients who fall into the category of frail
Keith Pratz, MD, explains how he is incorporating Vyxeos into his treatment of AML patients
Dr. Pratz tells us how he is incorporating Vyxeos (liposomal daunorubicin and cytarabine) into his practice for acute myeloid leukemia (AML) patients
Keith Pratz, MD, suggests strategies for clinicians when treating frail AML patients
Dr. Pratz offers his opinion on strategies for treating frail acute myeloid leukemia (AML) patients who do not quality for intensive therapy
Keith Pratz, MD, on exciting clinical data regarding FTL3 tyrosine kinase inhibitors in AML patients
Dr. Pratz evaluates some of the exciting clinical data with FLT3 tyrosine kinase inhibitors in acute myeloid leukemia (AML) patients presented at ASH 2017
Keith Pratz, MD, shares the outcome of the venetoclax study in treatment-naive AML patients
Dr. Pratz shares the outcomes of the venetoclax with decitabine or azacitidine study in treatment-naive acute myeloid leukemia (AML) patients
Keith Pratz, MD, on combining ivosidenib or enasidenib with chemotherapy in AML
Dr. Pratz considers whether we can combine ivosidenib or enasidenib with standard induction chemotherapy in newly diagnosed acute myeloid leukemia (AML) patients
Keith Pratz, MD, tells us about the epidemiology and cytogenetic risk associated with AML
Dr. Pratz discusses the epidemiology and cytogenetic risk associated with acute myeloid leukemia (AML)
Fredrick B. Hagemeister, MD, on the exploration of CAR T-cell therapies in various lymphoma types
Dr. Hagemeister offers his opinion on the effectiveness of CAR T-cell therapies outside of large cell lymphomas and whether we can apply this technology to other patient types
Fredrick B. Hagemeister, MD, describes how PD-1 inhibitors are being incorporated into FL treatment
Dr. Hagemeister explains how PD-1 inhibitors are being incorporated into follicular lymphoma (FL) treatment programs
Fredrick B. Hagemeister, MD, on managing toxicities associated with CAR T-cell therapies
Dr. Hagemeister on the safety of CAR T-cell therapies for lymphoma patients and recommendations for managing toxicities associated with these therapies
Fredrick B. Hagemeister, MD, on what we should know about CAR T-cell therapies
Dr. Hagemeister shares what physicians should know about the development of CAR T-cell therapies in lymphoid malignancies
Andrew Lane, MD, PhD, on minimal residual disease and AML treatment decisions
Dr. Lane discusses how minimal residual disease is being integrated into treatment decision making in acute myeloid leukemia (AML) patients
John Burke, MD, lists the top findings from ASH 2017 regarding lymphoid malignancies
Dr. Burke, shares his thoughts on the top findings at ASH 2017 regarding lymphoid malignancies
John Burke, MD, on combination atezolizumab, obinutuzumab, and bendamustine in follicular lymphoma
Dr. Burke, comments on the safety and efficacy of adding atezolizumab to obinutuzumab and bendamustine in patients with previously untreated follicular lymphoma
Habte Yimer, MD, considers the impact of combination obinutuzumab and bendamustine on CLL patients
Dr. Yimer on how the combination of obinutuzumab and bendamustine improves outcomes, quality of life and symptoms when given to untreated chronic lymphocytic leukemia (CLL) patients
Martin Hutchings, MD, details the role of PET in the management of Hodgkin’s lymphoma
Dr. Hutchings shares his thoughts on the role of PET in the treatment and management of Hodgkin’s lymphoma
Martin Hutchings, MD, considers how the ECHELON-1 study could be practice changing
Dr. Hutchings discusses how the results of the ECHELON-1 Phase 3 study in untreated Stage 3 or 4 Hodgkin’s lymphoma might change current practices
Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017
Dr. Wang tells us what exciting clinical data for acute myeloid leukemia (AML) patients was presented at ASH 2017
Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients
Dr. Wang, discusses what type of agents or treatment approaches a clinician should seek when managing frail acute myeloid leukemia (AML) patients
Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment
Dr. Wang, tells us how she is incorporating Vyxeos (liposomal daunorubicin and cytarabine) into her acute myeloid leukemia (AML) treatment strategy
Eunice Wang, MD, on strategies for frail AML patients who do not qualify for intensive therapy
Dr. Wang, suggests strategies for clinicians with frail acute myeloid leukemia (AML) patients who do not quality for intensive therapy
Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML
Dr. Wang elaborates on how minimal residual disease is being integrated into treatment decision making in acute myeloid leukemia (AML) patients
Michael Boxer, MD, on the effectiveness of fostamatinib in the maintenance of ITP responses
Dr. Boxer considers whether fostamatinib is effective in the maintenance of ITP responses
Parameswaran Hari, MD, MRCP, MS, on promising cellular immunotherapy studies from ASH 2017
Dr. Hari shares his opinion on the most exciting and promising studies regarding cellular immunotherapy presented at ASH 2017
David Miklos, MD, PhD, on the possible combination of ibrutinib and CAR T-cell therapies
Dr. Miklos considers the possibility that ibrutinib could be used in combination with CAR T-cell therapies when treating aggressive relapsed/refractory lymphomas
David Miklos, MD, PhD, explains how ibrutinib is being studied for the treatment of GVHD
Dr. Miklos shares how ibrutinib is being studied for the treatment of chronic graft versus host disease (GVHD) today
David Miklos, MD, PhD, describes the optimal way to use ibrutinib in the treatment of GVHD
Dr. Miklos outlines the optimal way to use ibrutinib in the treatment of chronic graft versus host disease (GVHD)
David Miklos, MD, PhD, on the outcomes of the ZUMA-1 clinical study
Dr. Miklos tells us about the outcomes of the ZUMA-1 clinical study and the long-term efficacy of CAR T-cell therapy
Michael Boxer, MD, on how obinutuzumab and bendamustine impacts quality of life in CLL patients
Dr. Boxer elaborates on how treating chronic lymphocytic leukemia (CLL) patients with obinutuzumab and bendamustine affects quality of life and symptoms
Michael Boxer, MD, considers broader uses for fostamatinib
Dr. Boxer offers his opinion on broader uses for fostamatinib
Robert Soiffer, MD, on other applications that IL-2 might have outside of treating chronic GVHD
Dr. Soiffer on other applications that IL-2 might have outside of treating chronic graft versus host disease (GVHD)
Robert Soiffer, MD, on some of the innovative approaches to treating chronic GVHD
Dr. Soiffer on some of the innovative approaches to treating chronic graft versus host disease (GVHD)
Robert Soiffer, MD, discusses current treatments available for chronic GVHD
Dr. Soiffer discusses current treatments available for chronic graft versus host disease (GVHD)
Robert Soiffer, MD, explains GVHD and some of the complications that come along with it
Dr. Soiffer explains chronic graft versus host disease (GVHD) and some of the complications that come along with it
Jane N. Winter, MD, discusses how CAR T-Cell therapies will impact the treatment of lymphomas
Dr. Winter discusses how CAR T-Cell therapies will impact the treatment of aggressive lymphomas
Jane N. Winter, MD, shares the clinical evidence supporting brentuximab vedotin in older patients
Dr. Winter shares the clinical evidence supporting the use of brentuximab vedotin in older patients with untreated classical Hodgkin’s Lymphoma
Jane N. Winter, MD, on whether checkpoint inhibitors can be used effectively in Hodgkin’s Lymphoma
Dr. Winter on whether checkpoint inhibitors can be used effectively in classical Hodgkin’s Lymphoma
Jane N. Winter, MD, explains how PD-1 and PD-L1 expression changes the way DLBCL is treated
Dr. Winter explains how PD-1 and PD-L1 expression changes the way Diffuse Large B-Cell Lymphoma (DLBCL) is treated
Andre Goy, MD, tells us about the long-term outcomes of the ZUMA-1 trial
Dr. Goy tells us about the long-term outcomes of the ZUMA-1 trial
Andre Goy, MD tells us about the BTK combination with lenalidomide in MCL
tells us about the BTK combination with lenalidomide in relapsed/refractory mantle cell lymphoma (MCL)
Andre Goy, MD, discusses the best strategy for using ibrutinib in MCL
Dr. Goy discusses the best strategy for using ibrutinib in mantle cell lymphoma (MCL)
John Gerecitano, MD, discusses the medical unmet needs in the treatment of follicular lymphoma
John Gerecitano, MD, discusses the medical unmet needs in the treatment of follicular lymphoma
John Gerecitano, MD, on what genetic predictors of response we have for follicular lymphoma
Dr. Gerecitano tells us what genetic predictors of response do we have for the treatment of follicular lymphoma
John Gerecitano, MD, discusses how PET staging affects outcomes and prognosis of follicular lymphoma
Dr. Gerecitano discusses how PET staging affects outcomes and prognosis of follicular lymphoma
John Gerecitano, MD, on predictors of response to tazemetostat in diffuse large B-cell lymphoma
Dr. Gerecitano on predictors of response to tazemetostat in diffuse large B-cell lymphoma
John Gerecitano, MD, talks about tazemetostat’s class and mechanism of action
Dr. Gerecitano tells us about tazemetostat’s class, mechanism of action, and what makes it unique
Miles Prince, MD, discusses I-O compounds and T-Cell Lymphoma treatment algorithms
Dr. Prince discusses how I-O compounds are being integrated into T-Cell Lymphoma treatment algorithms
Miles Prince, MD, on which emerging compounds for T-Cell Lymphomas look promising
Dr. Prince shares which emerging compounds in late stage development for T-Cell Lymphomas look promising at addressing unmet medical need
Miles Prince, MD, on the challenges to recruit and accrue patients to rare-cancer clinical studies
Dr. Prince discusses the challenges of trying to recruit and accrue patients to rare-cancer clinical studies
Miles Prince, MD, discusses the efficacy and safety of brentuximab vedotin to treat CTCL patients
Dr. Prince discusses the efficacy and safety of brentuximab vedotin when using it to treat Cutaneous T-Cell Lymphoma (CTCL) patients
Miles Prince, MD, on the role CD30 plays when selecting a treatment algorithm for CTCL patients
Dr. Prince on the role CD30 plays when selecting a treatment algorithm for newly diagnosed Cutaneous T-Cell Lymphoma (CTCL) patients
Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients
Dr. Prince tells us the issues and concerns to consider when choosing a treatment plan for newly diagnosed Cutaneous T-Cell Lymphoma (CTCL) patients
Sattva Neelapu, MD, on novel agents and up-front approaches showing efficacy in lymphomas
Dr. Neelapu discusses novel agents and up-front approaches showing efficacy in aggressive B-Cell lymphomas
Sattva Neelapu, MD, shares his approach to optimizing CAR T-Cell therapies
Dr. Neelapu shares his approach to optimizing CAR T-Cell therapies
Sattva Neelapu, MD, discusses efficacy results of the ZUMA-1 trial
Dr. Neelapu discusses the long-term efficacy results of the ZUMA-1 trial in patients with refractory aggressive Non-Hodgkin Lymphoma
John P. Leonard, MD, on the role social media plays in medicine
Dr. Leonard on the role social media plays in medicine
John P. Leonard, MD, on CAR-T cell therapies being developed for the treatment of lymphomas
Dr. Leonard explains how CAR-T cell therapies are being developed for the treatment of lymphomas
John P. Leonard, MD, on the role checkpoint inhibitors play in lymphoma treatment algorithms
Dr. Leonard on the role checkpoint inhibitors play in lymphoma treatment algorithms
John P. Leonard, MD, discusses novel agents for treating aggressive lymphomas
Dr. Leonard discusses what novel agents for treating aggressive lymphomas have the promise of improving outcomes
Gary Gordon, MD, PhD, on MRD endpoint for outcomes in the MURANO study
Dr. Gordon on how Minimal Residual Disease endpoint figures into the outcomes in the phase 3 MURANO study
Gary Gordon, MD, PhD, discusses safety concerns in the phase 3 MURANO clinical trial
Dr. Gordon discusses safety concerns in either regimen of the phase 3 MURANO clinical trial in Chronic Lymphocytic Leukemia patients
Gary Gordon, MD, PhD, discusses efficacy results of the phase 3 MURANO clinical trial
Dr. Gordon discusses efficacy results of the phase 3 MURANO clinical trial in Chronic Lymphocytic Leukemia patients
Matthew Davids, MD, on how checkpoint inhibitors are being developed for hematologic malignancies
Dr. Davids on how checkpoint inhibitors are being developed for post-allogeneic transplant hematologic malignancies
Sagar Lonial MD, FACP, on expectations for response in the challenging patient type
Dr. Lonial on what a physician can hope for in terms of response in the challenging patient type
Bruce D. Cheson, MD, on the role of nivolumab in Hodgkin Lymphoma
Dr. Cheson discusses the role of nivolumab in Hodgkin Lymphoma
Bruce D. Cheson, MD, discusses care, toxicities, and outcomes treating CLL patients with venetoclax
Dr. Cheson tells us the patterns of care, toxicities, and outcomes when treating CLL patients with venetoclax
Bruce D. Cheson, MD on choosing a front-line therapeutic regimen for CLL patients
Dr. Cheson on determinants to look for when choosing a front-line therapeutic regimen for Chronic Lymphocytic Leukemia patients
Sattva Neelapu, MD shares his advice for sites that are new to treating with CAR T-Cell therapies
Dr. Neelapu shares his advice for sites that are new to treating with CAR T-Cell therapies
Sattva Neelapu, MD shares safety results of the ZUMA-1 trial in patients with NHL
Dr. Neelapu shares long-term safety results of the ZUMA-1 trial in patients with refractory aggressive Non-Hodgkin Lymphoma
Matthew Davids, MD discusses his study using ibrutinib plus FCR in younger CLL patients
Dr. David tell us about the outcomes of his study using ibrutinib plus FCR in younger CLL patients
Matthew Davids, MD discusses how he typically treats front line CLL outside of a clinical study
Dr. Davids discusses how he typically treats front line CLL outside of a clinical study
John P. Leonard, MD discusses improving outcomes in high risk follicular lymphoma patients
Dr. Leonard discusses adding bortezomib to ofatumumab and bendamustine for induction in previously untreated high risk follicular lymphoma improve outcomes
Sagar Lonial MD, FACP tells us about the immunomodulatory mechanism of action of daratumumab
Dr. Lonial tells us about the immunomodulatory mechanism of action of daratumumab
Bruce D. Cheson, MD discusses the efficacy and safety of acalabrutinib in relapsed/refractory MCL
Dr. Cheson discusses the efficacy and safety of acalabrutinib in relapsed/refractory MCL
John P. Leonard, MD discusses lenalidomide plus rituximab for the treatment of MCL
Dr. Leonard discusses the combination of lenalidomide plus rituximab for the initial treatment of MCL
Sattva Neelapu, MD, on new targets being evaluated which could make CAR-T therapies more effective
Dr. Neelapu, Associate Professor and Director of Laboratory and Translational Research, Department of Lymphoma/Myeloma, MD Anderson Cancer Center, provides insight on which targets besides CD-19 are under evaluation and could make CAR-T therapies more effective
Sattva Neelapu, MD, on the possibility to enhance T-cell proliferation for a higher response rate
Dr. Neelapu, Associate Professor and Director of Laboratory and Translational Research, Department of Lymphoma/Myeloma, MD Anderson Cancer Center, weighs in on the possibility to enhance T-cell proliferation to achieve a higher response rate with CAR-T therapy
Sattva Neelapu, MD, on when we may see widespread availability of CAR-T therapies
Dr. Neelapu, Associate Professor and Director of Laboratory and Translational Research, Department of Lymphoma/Myeloma, MD Anderson Cancer Center, talks about the timing for widespread availability of CAR-T therapies and who will be administering them when they become available
Matthew Davids, MD, MMSc, on the potential benefits of utilizing checkpoint blockade
Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, relays what are the potential benefits of utilizing checkpoint blockade to enhance anti-tumor immunity in patients with hematologic malignancies who relapse post allogeneic hematopoietic cell transplantation
Matthew Davids, MD, MMSc, talks about his ASH 2016 presentations
Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, discusses his presentations from ASH 2016
Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML
Dr. Wang, Professor of Oncology, Department of Medicine Chief, Leukemia Service, Roswell Park Cancer Center, talks about how important drug potency is to selectivity in the treatment of FLT3-ITD positive AML
Andrzej Jakubowiak, MD, PhD, discusses which new drugs are most compelling
Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, talks about the new drugs worth mentioning
Andrzej Jakubowiak, MD, PhD, relays big changes in the evolving role of immunomodulatory therapy
Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, on big changes discovered in the ASH meetings in the evolving role of immunomodulatory therapy
Michael Kauffman, MD, on Selinexor regulatory and commercialization plans
Dr. Kauffman, CEO Karyopharm Therapeutics, discusses the regulatory and commercialization plans for Selinexor
Jeffrey Jones, MD, on the exciting CLL clinical advances presented at ASH 2016
Dr. Jones, Associate Professor of Medicine, The Ohio State University, The James Cancer Hospital, on which clinical advances in CLL presented at ASH 2016 were the most exciting
Edward Copelan, MD, on the most exciting presentations coming out of ASH 2016
Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, discusses which ASH 2016 presentations were the most exciting
David Miklos, MD, on developing an orphan drug for a small population of patients
Dr. Miklos, Associate Professor of Medicine, Blood and Marrow Transplantation, Stanford University, relays his pharmaceutical company experience in developing an orphan drug for a small population of patients
Miles Prince, MD, on if any positive news for CTCL patients will be coming out of ASH 2016
Dr. Prince, Professor, The University of Melbourne and Monash University, on ASH 2016 positive news for CTCL patients
Miles Prince, MD, on how CTCL patients will be impacted by treatment with brentuximab vedotin
Dr. Prince, Professor, The University of Melbourne and Monash University, on how he expects CTCL patients to be impacted by treatment with brentuximab vedotin
Jane Winter, MD, on how immunotherapies are being incorporated into treatment for lymphoma patients
Dr. Winter, MD, Northwestern Univ. Feinberg School of Medicine, Professor of Medicine, on the incorporation of immunotherapies into treatment algorithms for lymphoma patients
C. Ola Landgren, MD, PhD, on how physicians should manage patients who test MRD negative
Dr. Landgren, Chief, Myeloma Service, Memorial Sloan Kettering, discusses the best way for physicians to manage MRD negative patients
Swaminathan Iyer, MD, discusses exciting new CLL treatment options
Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, talks about exciting new treatment options for CLL
Swaminathan Iyer, MD, relays the latest T cell lymphomas news coming out of ASH 2016
Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, discusses the latest updates in T cell lymphomas that is being presented at ASH 2016
Swaminathan Iyer, MD, discusses intriguing data on CLL presented at ASH 2016
Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, on intriguing data for CLL coming out of ASH 2016
Alexander Perl, MD, on AML trial results presented at this year’s ASH meeting
Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, on which ASH AML trial results have been the moist surprising or impressive
Alexander Perl, MD, discusses treatment options for patients with FLT3-ITD positive AML
Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, gives his feedback on trials looking at treatment options for patients with FLT3-ITD positive AML who are refractory to or have relapsed after first-line treatment
Alexander Perl, MD, on prognosis, diagnosis and treatment strategies for AML
Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, discusses patient and hematologist challenges in the prognosis, diagnosis and treatment strategies for AML
Alexander Perl, MD, discusses treatment options for AML patients
Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, weighs in on AML treatment options in patients who are ineligible for intensive induction chemotherapy
Chadi Nabhan, MD, on attention grabbing presentation in CLL at ASH 2016
Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, on which ASH 2016 CLL presentations have caught your attention in CLL
Chadi Nabhan, MD, on payers using clinical pathways in hematological malignancies vs solid tumors
Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, on if payers are using clinical pathways in hematological malignancies the same way in solid tumors
Nikhil C. Munshi, MD, on whether we can start to associate the word “cure” with MM patients
Dr. Munshi, Director of Basic and Correlative Science, Jerome Lipper Multiple Myeloma Center, provides opinion on if the word “cure” can be associated with multiple myeloma patients
Lauren Pinter-Brown, MD, on improving quality of life for patients with T-cell lymphomas
Dr. Pinter-Brown, Health Sciences Professor of Medicine and Dermatology; Chao Family Comprehensive Cancer Center, University of California, Irvine, explains how novel therapies improve the quality of life for patients with T-cell lymphomas
Lauren Pinter-Brown, MD, explains refractory vs. relapsed peripheral T-cell lymphoma patients
Dr. Pinter-Brown, Health Sciences Professor of Medicine and Dermatology; Chao Family Comprehensive Cancer Center, University of California, Irvine, explains the outcome differences between primary refractory vs. relapsed peripheral T-cell lymphoma patients
Frederick Locke, MD, on the timing of when we could see widespread availability of CAR-T therapies
Dr. Locke, Director of Research and Service Chief of the Immune and Cellular Therapy (ICE-T) Program, Moffitt Cancer Center, provides insight into when widespread availability of CAR-T therapies will be available
Frederick Locke, MD, on if CAR-T may replace transplantation when treating B-cell lymphomas
Dr. Locke, Director of Research and Service Chief of the Immune and Cellular Therapy (ICE-T) Program, Moffitt Cancer Center, talks about whether CAR-T therapies could replace transplantation when treating aggressive b cell lymphomas
Frederick Locke, MD, explains the ZUMA-1 results and what it means to DLBCL patients
Dr. Locke, Director of Research and Service Chief of the Immune and Cellular Therapy (ICE-T) Program, Moffitt Cancer Center, speaks to the results of ZUMA-1 and what it means to diffuse large B cell lymphoma patients
Parameswaran Hari, MD, on stem cell transplant and the treatment of high and low risk MM patients
Dr. Hari, Professor of Hematology, Medical College of Wisconsin, talks about how stem cell transplant figures into the treatment algorithm for both high risk and low risk multiple myeloma patients
Parameswaran Hari, MD, discusses stem cell transplantation and the treatment of myeloma
Dr. Hari, Professor of Hematology, Medical College of Wisconsin, explains how to integrate stem cell transplantation into the treatment of myeloma
Aref Al-Kali, MD, explains sustained inhibition of FLT3 when treating AML patients
Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, reflects on the BEAT AML master trial and individualized therapy for AML patients
Aref Al-Kali, MD, reflects on the BEAT AML master trial and individualized therapy for AML patients
Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, reflects on the BEAT AML master trial and individualized therapy for AML patients
Aref Al-Kali, MD, explains how the CPX 351 data may impact how AML patients are treated if approved
Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, explains how the CPX 351 data may impact the market and how AML patients are treated if approved
Michael Kauffman, MD, on how Selinexor works
Dr. Kauffman, CEO Karyopharm Therapeutics, on how Selinexor works
Chadi Nabhan, MD, on incorporating clinical pathways into CLL and other hematologic malignancies
Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, discusses how clinical pathways are being incorporated into CLL and other hematologic malignancies
Chadi Nabhan, MD, weighs in on the treatment of elderly patients with hematological malignancies
Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, provides insight on how elderly patients with hematological malignancies should be treated
Eunice Wang, MD, on exciting news stemming from this year’s ASH meeting in the treatment for ALL
Dr. Wang, Professor of Oncology, Department of Medicine Chief, Leukemia Service, Roswell Park Cancer Center, gives her view on exciting news coming out of this year’s ASH meeting related to the treatment for ALL
Matthew Davids, MD, relays the most exciting clinical advances in CLL at ASH 2016
Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, on clinical advances in CLL presented at ASH 2016
Andrzej Jakubowiak, MD, PhD, on the key takeaways from presentations at ASH 2016 on KRD
Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, talks bout the key takeaways from ASH 2016 presentation on KRD, including the STaMINA trial
Matthew Davids, MD, talks about the advances in CLL and the unmet medical need for these patients
Dr. Davids, Associate Director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, talks about the advances in CLL and the unmet medical needs for these patients
Eunice Wang, MD, talks about the challenges in treating elderly patients with AML
Dr. Wang, Professor of Oncology, Department of Medicine Chief, Leukemia Service, Roswell Park Cancer Center, discusses challenges and strategies to overcome when treating elderly patients with AML
Andrzej Jakubowiak, MD, PhD, on the role of selinexor and the STORM trial and its future development
Dr. Jakubowiak, University of Chicago, Professor of Medicine; Director, Myeloma Program, talks about the role of selinexor and the STORM trial and its development moving forward
Jeffrey Jones, MD relays the outcomes in his study for refractory, progressing CLL patients
Dr. Jones, Associate Professor of Medicine, The Ohio State University, The James Cancer Hospital, talks about the outcomes in his study for refractory/progressing CLL patients
Jeffrey Jones, MD, talks about the unmet medical need based on significant advances for CLL patients
Dr. Jones, Associate Professor of Medicine, The Ohio State University, The James Cancer Hospital, speaks about the unmet medical need based on significant advances for CLL patients
Edward Copelan, MD, on how he reduced the number of days for donors to provide cells for autologous BMT
Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, on how he reduced the number of days for donors to provide cells for autologous BMT
Edward Copelan, MD, discusses the Levine Cancer Institute Program
Dr. Copelan, Chair, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, talks about his Levine Cancer Institute program
David Miklos, MD, on the impact stem cell and bone marrow transplant have on patients
Dr. Miklos, Associate Professor of Medicine, Blood and Marrow Transplantation, Stanford University, on how stem cell and bone marrow transplant related illnesses impact outcome in leukemia and lymphoma patients
David Miklos, MD, discusses the outcomes in the phase 2 ibrutinib study for chronic GvHD
Dr. Miklos, Associate Professor of Medicine, Blood and Marrow Transplantation, Stanford University, explains the phase 2 ibrutinib study outcomes for chronic graft-versus host disease
Miles Prince, MD, explains the outcomes of the ALCANZA study in CD30-expressing CTCL
Dr. Prince, Professor, The University of Melbourne and Monash University, talks about the outcomes of the ALCANZA study in CD30-expressing CTCL
Jane Winter, MD, talks about how personalized medicine is being applied to NHL
Dr. Winter, Northwestern Univ. Feinberg School of Medicine, Professor of Medicine, weighs in on how personalized medicine is being applied to NHL
Jane Winter, MD, relays the most exciting news at ASH 2016 for NHL patients
Dr. Winter, MD, Northwestern Univ. Feinberg School of Medicine, Professor of Medicine, on her findings of the most exciting news at ASH 2016 for NHL patients
Swaminathan Iyer, MD, on how romidepsin can be incorporated into the treatment of T cell lymphoma
Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, discusses how romidepsin should be incorporated into the treatment of patients with relapsed or refractory angioimmunoblastic T cell lymphoma
Swaminathan Iyer, MD, discusses how to incorporate ofatumumab into the treatment of CLL
Dr. Iyer, Co-Director Cockrell Center for Advanced Therapeutics, on how physicians should incorporate ofatumumab into the treatment of untreated CLL patients
Alexander Perl, MD, on how the BEAT AML master trial will change the way AML patients are treated
Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, talks about how the BEAT AML master trial will change the way AML patients are treated
Alexander Perl, MD, discusses how molecular testing can facilitate decision making in AML patients
Dr. Perl, Assistant Professor of Medicine, Division of Hematology/Oncology, University of Pennsylvania, on how molecular testing can be used to facilitate clinical decision-making in AML patients
Sattva Neelapu, MD, explains what the results of ZUMA-1 mean to DLBCL patients
Dr. Neelapu, Director of Laboratory and Translational Research, MD Anderson Cancer Center, explains what the results of ZUMA-1 mean to diffuse large B-cell lymphoma patients
Sattva Neelapu, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19
Dr. Neelapu, Director of Laboratory and Translational Research, MD Anderson Cancer Center, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19
Lauren Pinter-Brown, MD, updates us on the important studies in T-cell lymphomas presented at ASH
Dr. Pinter-Brown, Professor of Medicine and Dermatology, UC Irvine, updates us on the important studies in T-cell lymphomas presented at ASH 2016
Lauren Pinter-Brown, MD, updates us on the important studies in cutaneous lymphomas presented at ASH
Dr. Pinter-Brown, Professor of Medicine and Dermatology, UC Irvine, updates us on the important studies in cutaneous lymphomas presented at ASH 2016
Frederick L. Locke, MD, discusses what new targets could make CAR-T therapies more effective
Dr. Locke, Service Chief of the Immune and Cellular Therapy Program, Moffitt Cancer Center, discusses what new targets could make CAR-T therapies more effective
Frederick L. Locke, MD, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19
Dr. Locke, Service Chief of the Immune and Cellular Therapy Program, Moffitt Cancer Center, discusses the results of the ZUMA-1 pivotal phase 2 study with KTE-C19
Susan O’Brien, MD, shares her thoughts on the advancements in the treatment of leukemia at ASH 2016
Dr. O’Brien, Professor of Medicine, University of California, Irvine, shares her thoughts on the advancements in the treatment of leukemia at ASH 2016
Susan O’Brien, MD, discusses CLL presentations at ASH 2016
Dr. O’Brien, Professor of Medicine, University of California, Irvine, discusses CLL presentations at ASH 2016
Parameswaran Hari, MD, discusses the latest developments in stem cell transplantation at ASH 2016
Dr. Hari, Professor of Hematology, Medical College of Wisconsin, discusses the latest developments in stem cell transplantation here at ASH 2016
Aref Al-Kali, MD, talks about the importance of the AGIOS 221 data
Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, talks about the importance of the AGIOS 221 data
Aref Al-Kali, MD, discusses CPX 351 in older high-risk patients in AML
Dr. Al-Kali, Assistant Professor of Medicine, Mayo Clinic, discusses CPX 351 in older high-risk patients in AML
Shaji Kumar, MD, discusses venetoclax and why it stands out as one of the most promising compounds being presented at ASH 2016
Dr. Kumar, Professor of Medicine, Mayo Clinic, Rochester, discusses venetoclax and why it stands out as one of the most promising compounds being presented at ASH 2016
Shaji Kumar, MD, discusses selinexor and why it stands out as one of the most promising compounds being presented at ASH 2016 (part 2)
Dr. Kumar, Professor of Medicine, Mayo Clinic, Rochester, discusses selinexor (KPT-330) and why it stands out as one of the most promising compounds being presented at ASH 2016
Precision Medicine Coming to Bone Marrow Transplant
Navneet Majhail, MD Director of the Blood and Marrow Transplant Program Cleveland Clinic discusses the fact that Precision Medicine Coming to Bone Marrow Transplant.
Venetoclax Produces Good Responses for 17p Deletion May Be Approved in 2016
Susan M. O’Brien, MD Medical Director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research UC Irvine talks about how Venetoclax Produces Good Responses for 17p Deletion May Be Approved in 2016.
Advances In B-Cell Lymphoma From ASH 2015
Steven T. Rosen, M.D. Director of the Comprehensive Cancer Center City of Hope discusses the latest Advances In B-Cell Lymphoma From ASH 2015
Real World Experience Idelalisib - Rituximab Combination for Relapsed CLL
Jennifer R. Brown, MD Director, Chronic Lymphocytic Leukemia Center Dana-Farber Cancer Institute talks about Real World Experience with Idelalisib - Rituximab Combination for Relapsed CLL.
Follow @OBRTweets